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To Chiara and Irene, 
My dear friends 
 
“…..we have been out in the woods all night 
A-conjuring Summer  in! 
And we bring you news by word of mouth- 
Good news for cattle and corn- 
Now is the Sun come up from the South,…” 
 
(Puck of Pook’s Hill- Rudyard Kipling) 
 
 
5 
 
Abstract 
 
Epigenetic gene regulation is a major  mechanism of cancer initiation and 
progression, through the inactivation of several tumor suppressor genes. Emerging 
evidence indicates that epigenetics may also play a key role in the development of 
chemoresistance. Polycomb group genes (PcGs) are epigenetic effectors, essential 
for cancer stem cell self-renewal and pluripotency and have been the focus of 
investigation in cancer research in the last years. Two main Polycomb repressive 
complexes (PRC1, PRC2) mediate gene silencing through histone post-translational 
modifications.  Several solid tumors including colorectal cancer, pancreatic ductal 
adenocarcinoma, cholangiocarcinoma and breast cancer show an over-expression of  
EZH2 (PRC2 component)  and BMI-1 (PRC1 component). EZH2 and BMI-1 are  
two main PcG genes directly involved in the aggressiveness of a tumor, predicting 
poor prognosis, metastasis and chemoresistance. As we will show in this 
dissertation,  Mel-18 (PRC1 component)  may function as a tumor-suppressor by 
competing with BMI-1, modulating tumor aggressiveness and inhibiting metastases 
in breast cancer. We found genetic polymorphisms of EZH2 significantly associated 
to colorectal cancer patiens outcome. This results could be an important tool to 
predict the clinical outcome. Moreover, EZH2 was identified as an attractive target 
and we investigated the interaction of the EZH2-inhibitor 3-Deazaneplanocin A 
(DZNeP) with gemcitabine in pancreatic cancer and we showed the synergism that 
impairs cancer stem cell self-renewal and tumorigenicity. Despite the well-
established role of PcGs in cancer stem cell biology, few studies dissected the 
clinical significance of these genes. In this thesis, through functional studies, 
combination therapy and correlation of single nucleotide polymorphisms with the 
clinical outcome we explore PcGs as predictive and prognostic factors in oncology, 
with particular emphasis to the identification of novel important biomarkers. 
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1. Colorectal Cancer: Epidemiology, Pathogenesis and Treatment  
Metastatic colorectal cancer (mCRC) is one of the leading causes of cancer death in 
Western countries. Worldwide, 1.2 million new colorectal cancer cases were detected in 
2008, and 608,700 deaths have been estimated [1].  
Several exciting advancements on factors predisposing to colorectal cancer have been 
defined. Recently, It has been shown that a part of these tumours are hereditary and, thus, 
transmitted from one generation to the next. The environmental factors (diet and lifestyle) 
seem to play a certain role in the development of colorectal cancer [2]. There is evidence 
that adenomatous polyps represent the natural precursor of intestinal malignancies, and that 
their systematic removal may prevent cancer occurrence [3]. Most colorectal malignancies 
develop from preexisting adenomatous polyps that are less than 1 cm in diameter and 
associated with malignant changes and their frequency increases with age. There is 
clinical, epidemiological and experimental evidence clearly indicating that adenomatous 
polyps represent the natural precursor of carcinoma; this, however, does not mean that all 
polyps evolve into cancer, and does not rule out the possibility of “de novo” (i.e., from 
apparently flat mucosa) carcinogenesis. The most common include inactivation of tumour 
suppressor genes, activation of oncogene (by mutation, overexpression, amplification or 
other mechanisms), functional or mutational inactivation of a class of genes involved in 
repairing DNA mismatches (MMR genes), and abnormal DNA methylation. Finally, 
changes in the methylation pattern of DNA have frequently been reported in colorectal 
tumourigenesis [4]; DNA hypermethylation can inhibit the transcription of tumour 
suppressor and of mismatch repair genes, thus providing an alternative explanation for 
gene inactivation during colonic cancer development [5].  
Colorectal cancer prognosis and treatment strategies are highly dependent on tumor stage. 
Stage I colorectal cancer, which is confined to sub-mucosa, shows a 5-year survival rate of 
approximately 90% [6]. On the other hand, metastatic colorectal cancer patients (stage IV) 
treated with the best supportive care, have a median survival of just 6 months. For non-
metastatic patients, surgical excision is the preferred option. Adjuvant chemotherapy is 
employed after surgical resection in stage III patients (localized tumor with lymph node 
invasion), while it is questionable for stage II patients (localized tumor without lymph node 
invasion) [7]. Adjuvant treatment is based on 5-fluorouracil (5-FU) alone or in 
combination with oxaliplatin. Stage IV disease is treated with doublet chemotherapy, 
including 5-FU plus either oxaliplatin or irinotecan. Doublet chemotherapy plus biological 
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agents (anti-angiogenic or anti-epidermal growth factor receptor (EGFR) molecules) 
increase stage IV patients’ median survival to approximately 2 years [6]. Individual and 
tumor genetic background can significantly affect patient’s response to a drug and thus the 
choice of treatment. In keeping with this hypothesis, it has been shown that only patients 
with wild-type KRAS tumors respond to anti-EGFR therapy [8-10]. Even with some 
progress in molecular characterization of drug sensitivity, tailored therapy for colorectal 
cancer patients is still a challenge. Molecular determinants of response to 
chemotherapeutic agents, which are still the cornerstone of colorectal cancer therapy, are 
lacking [11].  
 For the majority of mCRC patients, chemotherapy with a fluoropyrimidine plus either 
irinotecan or oxaliplatin combined with a biologic agent is nowadays considered the 
preferred treatment option in first line [11]. In particular, bevacizumab improved the 
efficacy of chemotherapy alone in several phase III trials [12] and is approved in 
combination with fluoropyrimidine-based chemotherapy for the first- or secondline 
treatment of mCRC patients 
(http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s01 691bl.pdf). 
Despite these substantial changes in the clinical management of mCRC, long-term 
prognosis remains unfavorable, median overall survival (OS) not exceeding 24 months 
even in most recent studies [13]. Results from clinical trials and everyday practice show 
that mCRC patients’ outcome widely varies according to several factors. Up to now, 
reliable prognostic parameters are represented by basal clinical and laboratory variables 
[14]. With few promising exceptions [15], validated molecular markers of disease course 
are still lacking. Recent evidence indicates that colorectal cancer (CRC) is a stem cell 
driven disease. Colorectal cancer stem cells (CSCs) are identified based on CD133 surface 
marker expression and account for <3% of the tumor mass. They share with normal stem 
cells the ability to self-renew and to differentiate into many cell types. In addition, 
colorectal CSCs display a unique tumorigenic potential [16], are more resistant to 5-
fluorouracil-based chemotherapy [17] and more invasive than the other tumor cells [18]. 
For these reasons, CSCs are thought to be the seeds of tumor initiation, therapy resistance 
and metastatic spreading [19]. Thus, the identification of molecular markers predicting 
CSC activity could provide innovative tools to stratify mCRC patients and optimize 
treatment choices. 
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2. Pancreatic Cancer and Cholangio-carcinoma 
 
2.1 Epidemiology, pathogenesis and treatment of Pancreatic cancer 
 
With a 5-year survival rate of less than 5 percent, pancreatic ductal adenocarcinoma 
(PDAC) is the most lethal among the major solid tumors [1]. Despite extensive 
clinical and scientific efforts, the grim prognosis of this disease has not improved 
over the past decade [2]. The main reasons for the lack of efficient therapeutic 
strategies include invasive behavior and intrinsic resistance to most chemo-/radio- 
and immuno-therapy regimens [3].  
 Recently PDAC emerged as a Cancer Stem Cell (CSC) – driven disease. 
Pancreatic CSCs are highly tumorigenic and have the abilities to self-renew and 
produce differentiated progeny. Pancreatic CSCs possess the ability to undergo 
epithelial-mesenchymal transition (EMT) [4] and form spheroids in serum-free-
medium containing well-defined growth factors. The PDAC spheroids showed 
increased proliferation, invasiveness, and metastasis [5]. CSCs have also been 
associated with chemoresistance to gemcitabine [6-8]. Against this background, 
studies on key determinants in CSCs can provide both biomarkers of PDAC 
aggressiveness and optimal novel targets to overcome chemoresistance.  
 
2.2 Epidemiology, pathogenesis and treatment of Cholangiocarcinoma  
 
Cholangiocarcinoma (CCA) is a malignancy arising from the biliary tract 
epithelium [9]. CCA is rare, with an annual incidence of 2-3 cases per 100,000 
individuals in the Western population [10]. However, it is the second most common 
primary hepatic malignancy, with recent epidemiological studies suggesting a 
progressively increasing incidence in Western countries [11-13]. Anatomically, 
CCA is classified as intrahepatic (IH-CCA) or extrahepatic (EH-CCA). IH-CCA 
arises from the intrahepatic ducts, which extend from the periphery of the liver to 
the second-order bile ducts within the liver [14]. EH-CCA is observed and defined 
in three different growth patterns: periductal infiltrating, papillary or intraductal 
and mass forming [15]. The high mortality rate of CCA is mainly due to its 
aggressive behavior. Indeed, the majority of these tumors are diagnosed at a late 
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stage of disease progression, precluding surgical therapies [16,17]. Furthermore, 
CCA is characterized by a marked resistance to chemotherapy [18,19]. Several 
drugs have been tested in phase II studies in unresectable CCA (5-fluorouracil, 
gemcitabine methasulfon-m-anisidide, cisplatin, rifampicin, mitomycin C and 
paclitaxel) with partial response rates below 9% and average survival shorter than 
12 months [18]. Therefore, studies for the identification of key factors that play a 
critical role in tumor chemosensitivity/resistance for the selection of patients with 
the highest likelihood of responding to these therapies are urgently required.  
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3. Breast Cancer: Epidemiology, Pathogenesis and Treatment of 
Triple Negative Breast Cancer 
 
Breast cancer (BC) is a major cause of morbidity and mortality worldwide. BC 
accounts for 23% of all cancer cases in the United States and continues to be the 
main cause of cancer-related deaths among females [1]. Many studies have 
demonstrated that breast carcinogenesis is driven by genetic and epigenetic 
alterations. Recent studies have shown that epigenetic regulation could have a 
potential therapeutic and prognostic role in BC.  
   
3.1 Triple Negative Breast Cancer  
 
The triple-negative breast cancer (TNBC) constitutes approximately 15% of all 
mammary tumors and identifies a subgroup characterized by the lack of 
expression for the estrogen receptor (ER), the progesterone receptor (PgR) and 
for the epidermal growth factor (HER2). TNBC also differs from other subtypes 
of breast cancer in being the most aggressive subtype of BC which is associated 
with a poor prognosis. In fact,  the risk of relapse for a patient diagnosed with 
early-stage TNBC is around 60% [2]. Based upon gene expression profile 
analyses, TNBC frequently has molecular characteristics of basal-like tumors, 
such as the absence of expression of ER, PgR and HER2, basal expression of 
cytokeratins (CK5 / 6 and CK17), overexpression of EGFR, mutations in p53, 
frequent loss of function of BRCA1, high proliferation index and high tumor 
grading. The correlation between the two phenotypes, triple negative (TN) and 
basal-like, however, is not complete, with 20% of basal-like tumors that express 
an immunohistochemical phenotype different from TN, whereas 20% of TNBC 
do not express the molecular phenotype of basal-like tumors [2-4]. Recently, a 
new subgroup of breast cancers has been identified within the group of triple 
negative tumors referred to as tha "claudin low" subtype. These represent 5% of 
breast cancers and seem to express some characteristics of stem cells [2-5]. 
Also, from the clinical point of view, the triple-negative phenotype is a 
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heterogeneous group of diseases characterized by a different natural history and 
prognosis.  
The majority of cases of TNBC represent a biologically aggressive disease with 
early age of onset, high recurrence rates both of local and systemic disease, 
especially in the early years following diagnosis, and poor prognosis despite 
treatment. Compared to the other subtypes, TNBC shows a higher rate of 
relapse and visceral and encephalic localization, which, in some series reach up 
to 40-50% of cases [6,7]. In a minority of cases, however, TNBC behaves 
biologically less aggressively with survival comparable to other subtypes of 
breast cancer [8]. Some of rare histotypes, including the apocrine, the adenoid 
cystic, which present a triple-negative phenotype are characterized by a 
favorable prognosis [6]. From the therapeutic point of view, the resistance to 
hormonal treatments and anti-HER2 and the lack of specific treatments for the 
TNBC results in chemotherapy being the treatment of choice for this disease. In 
particular, data from retrospective studies conducted in a large series in the 
neoadjuvant setting show that TN tumors exhibit a high rate of pathological 
complete response (pCR) to treatment including anthracyclines and taxanes 
which correlates to a better outcome [9]. Therefore, chemotherapy including 
anthracyclines and taxanes represents the most commonly used neoadjuvant 
and adjuvant treatment for TNBC.  
Our increasing understanding of the mechanisms involved in the 
development of these tumors, and in particular the frequent alteration of 
BRCA1 and the mechanisms of DNA repair, which appear to be shared among 
the TNBC BRCA-associated and sporadic tumors, has provided the rationale 
for the study of alkylating agents and platinum derivatives in this group of 
patients. However, the retrospective nature of clinical trials, in one case, and the 
small sample size in the other, do not allow definitive conclusions about the real 
activity and efficacy of these compounds in clinical practice. For example, a 
retrospective study of 108 patients with BRCA-mutations demonstrated a pCR 
rate of 80% to a neoadjuvant treatment with cisplatin compared to 20% of 
protocols not containing this drug [10]. At the same time in another prospective 
study of 28 patients with TNBC subjected to a treatment with neoadjuvant 
cisplatin, a pCR of only 22% [11]. Regarding the metastatic setting, the 
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possible options of chemotherapy for TNBC do not differ from those 
commonly used in other subtypes of breast cancer (mono-chemotherapies, 
association of chemotherapy and bevacizumab). Despite the strong biological 
rationale for the use of PARP inhibitors, studies with drugs directed against 
TNBC potential targets that are overexpressed, including EGFR and PARP 
(Poly ADP Ribose Polymerase) did not produce significant improvements in 
clinical outcomes. TNBC represents a subgroup of extremely heterogeneous 
tumors on the molecular and clinical levels and for this reason, the achievement 
of an improved outcome of these patients will require a greater understanding 
of the biology of this disease as well as the identification of prognostic and 
predictive factors aimed at further individualization of treatment. One emerging 
avenue for targeting TNBC is the Polycomb complex of genes (PcG) that plays 
an important role in breast cancer and in particular, TNBC.  
This research strategy may also help to identify novel molecular mechanisms of 
progression for TNBC, paving the way to innovative treatment strategies. 
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4. Polycomb Group Genes are essential for Cancer Stem Cells’ self-
renewal 
  
4.1 Cancer Stem Cells (CSC) hypothesis   
 
For several years, cancer progression has been viewed as a stochastic process, 
driven by evolutionary laws. The classical multi-hit paradigm, drawn by 
Vogelstein for colorectal cancer, was extended to virtually all neoplasms [1]. 
According to this view, cancer originates and develops as a sequence of genetic 
mutations occurring in a population of malignant cells. Each mutation is 
random, and each cancer cell has the same probability to acquire advantageous 
mutations, thereby overriding all other clones. This simple vision led to the 
discovery of several cardinal genes in cancer, like p53 or the epidermal growth 
factor receptor (EGFR). However, it often failed to identify novel targets to 
improve cancer treatment [2]. One paradox deriving from this reductionist 
paradigm is represented by mouse models. If cancer is simply a genetic disease, 
mouse and human cancer should behave very similarly, since the two species 
share more than 75% of the genome [3]. As we will see in the next sections, 
mouse models still constitute a milestone of preclinical drug efficacy tests. 
However, they have sometimes failed in predicting the efficacy of epigenetic 
drugs. Preclinical models predicted that the epigenetic drug decitabine could 
delay hormone resistance onset in prostate cancer, thereby prolonging survival 
[4]. Unfortunately, clinical trials showed a very modest activity of this drug in 
hormone refractory prostate cancer patients [5]. The difference between mouse 
models and human cancer likely resides in several molecular features, including 
gene function and structure [6], physiological gene expression levels [7] and 
epigenetic gene regulation [8]. Epigenetics is defined as the sum of all heritable 
changes that are not due to alterations in DNA primary structure [9]. Epigenetic 
information is stored as DNA methylation, histone covalent modifications and 
RNA interference. All these mechanisms have been shown to substantially 
contribute to cancer initiation, prognosis and response to therapy [10]. Unlike 
DNA alterations, epigenetic changes are reversible, and thus are attractive 
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targets for cancer therapy. Interestingly, new epigenetic drugs are emerging as 
anticancer agents, and few of them have been already approved as standard 
treatments for human malignancies [11]. Another lasting dogma in cancer 
research is the idea that all cancer cells have the same probability to mutate and 
drive cancer progression. According to this assumption, all cancer cells are 
equally dangerous and must be killed in order to achieve complete remission. 
Recent evidence suggests that cancer is indeed organized as a hierarchy, with 
cancer stem cells (CSCs) at the apex [12]. These cells are the only tumor-
initiating clones, and often represent a small fraction of total tumor volume. If 
the CSCs hypothesis is true, current treatments that aim at reducing the bulk 
tumor mass could be ineffective. New treatments specifically targeting the CSC 
population are warranted [11]. As we will see in the following sections, PcGs 
are a fundamental link between epigenetic plasticity and CSC biology [13,14]. 
A large amount of pre-clinical studies showed that PcGs are involved in CSC 
self-renewal, metastatization and therapy resistance. The present review will 
summarize this evidence, and will suggest how this information could be used 
to develop new therapeutic strategies and to allow a molecular stratification of 
patients. We will particularly focus on solid tumors, because we think that the 
identification of novel biomarkers and promising therapeutic targets is 
particularly warranted in this field. The CSC paradigm proposes that the 
generation and pro-gression of any tumor is driven by a small subpopulation of 
the tumor mass [15]. According to this hypothesis, only a small fraction of cells 
within certain tumors are able to form tumors in vivo [1]. In 1970, Salmon 
introduced this concept, affirming that CSCs are responsible for initiation and 
prolif-eration of a tumor mass [16]. CSCs have been first identified in acute 
myeloid leukemia (AML). Leukemia stem cells iso-lated in the CD34+CD38− 
fraction constitute less than 5% of the bulk tumor. When injected in NOD/SCID 
mice, this sub-population is able to generate leukemic cells that resemble the 
original ones [12]. Subsequently, CSCs have been isolated from human solid 
tumors, which are the focus of the present review. Indeed, breast CSCs express 
a CD44+/CD24− phe-notype [15]. This concept was then expanded to brain 
tumors, where neural CSCs express the CD133 transmembrane sur- face 
antigen [17]. Using CD133 as a selective marker, CSCs have also been 
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described in primary melanoma, colon cancer and human prostate [18–21]. Kim 
et al. have been able to iso-late lung stem cell using the markers Sca-1 and 
CD34 [22]. Finally, pancreatic CSCs express a tumorigenic CD44+ESA+ 
surface phenotype [23]. Nowadays, CSCs have been identi-fied in most solid 
tumors through different markers (CD133, CD44, CD24, CD34 and ESA) that 
are specific for different cancer types (Table 1). 
                        
Like normal stem cells (SCs), CSCs have an unlimited self-renewal potential, 
and show the ability to differentiate into many cancer cell types. They are 
chemotherapy resistant [11], and are thought to be the seeds of metastatic 
spreading [24]. CSC origin is still unclear; however, their formation could 
depend on genetic and epigenetic alterations. Two main hypotheses can explain 
the CSCs formation. The first hypothesis is that CSCs originate from a SC 
acquiring genetic mutations leading to uncontrolled proliferation. According to 
the second hypothesis, CSCs can arise from mutations of differentiated cancer 
cells that activate a specific transcription factor and re-acquire self-renewal 
potential [25]. Despite a significant amount of data in favor of the CSC 
hypothesis, some studies questioned the assumption that this subpopulation 
could be identified by one or few surface markers [26]. Thus, it is likely that the 
identification of key pathways for CSC self-renewal, chemo-resistance or 
invasion could clarify the biological and clinical relevance of the CSC 
hypothesis.  
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4.2 Polycomb group mechanism in cancer 
 
PcGs are essential epigenetic regulators for SC biology [13]. Epigenetic gene 
modulation is mediated by two main mechanisms: DNA methylation and 
histone post-translational modifications. The latter includes methylation, 
acetylation and ubiquitylation at specific aminoacidic residues. Each histone 
modification is able to activate or repress gene expression, according to a 
specific histone code [27]. Polycomb proteins are organized in two main 
Polycomb repressive complexes (PRCs): PRC1 and PRC2 [13]. PRCs are 
involved in gene silencing, through specific mechanisms (Fig. 1).  
 
           
Fig. 1. Epigenetic mechanism of gene silencing. PRCs may activate gene silencing 
directly (black arrows), or through DNA methylation (grey arrows). MAPK (mitogen 
activated protein kinase) pathway activates, while AKT pathway inactivates PRC2. In turn, 
PRC1 enhances AKT kinase activity. PRC: Polycomb repressive complex; EZH2: 
enhancer of zeste homologue-2; EED: embryonic ectodermal development; SUZ12: 
suppressor of zeste 12 homolog; H3K27me3: histone H3 Lys 27 thrimethylation; BMI-1: 
B-cell-specific Moloney murine leukemia virus integration site 1; Mel18, Polycomb group 
RING finger protein 2; RING1: really interesting new gene 1 protein; CBX: chromobox 
homolog; H2AK119ubi: histone H2A Lys 119 ubiquitylation; DNMT: DNA methyl 
transferase.  
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Due to the clinical purpose of the present review, we will not discuss other 
variants of the PRCs: moreover, we will focus on PRC1 and PRC2 catalytic 
subunits as they have been extensively studied in human cancers. The catalytic 
component of PRC2 is EZH2 (Enhancer of Zeste Homologue 2) which 
mediates histone H3 Lys 27 trimethylation [13]. This process contributes to the 
recruitment of PRC1, which completes gene silencing through the histone H2A 
ubiquitylation. BMI-1 (B-cell-specific Moloney murine leukemia virus 
integration site 1) is the catalytic sub-unit of PRC1. Gene silencing is also 
mediated by direct interaction between Polycomb proteins, EZH2 and DNA 
methyl-transferases (DNMTs), which ties a methyl to DNA and triggers 
transcriptional repression in somatic cells [13]. The fundamental role of PcGs in 
SCs maintenance prompted many groups to investigate their function in CSC 
self-renewal. PRCs control CSC proliferation in different models. BMI1 
knockdown in medulloblastoma cells significantly prevents tumor formation in 
vivo [28]. Similar results were found in Ewing sarcoma [29], and prostate 
cancer [30]. In addition, EZH2 is crucial for breast CSC proliferation [31] and 
its specific silencing impairs glioblastoma multiforme CSC self-renewal in vitro 
and tumor initiating capacity in vivo [32]. In keeping with these pre-clinical 
data, EZH2 and BMI1 are over expressed in different types of cancer and this 
phenomenon is often related to poor prognosis, metastases, high grade and 
stage, chemoresistance and tumor aggressiveness (Table 2).  
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With few notable exceptions, summarized in Fig. 2, epigenetic mechanisms of gene 
silencing by PcGs have not been linked to CSC features (invasion, chemo-
resistance). The role of PcGs in cancer could be related to an interesting mechanism 
of silencing through the repression of anti-metastatic genes. Tumor invasion is 
characterized by decrease of Ecadherin expression and consequent disruption of 
cell–cell adhesion. EZH2 mediates E-cadherin silencing through histone H3 Lys27 
trimethylation [33]. EZH2 up-regulation and consequent E-cadherin silencing have 
been correlated to tumor progression, invasiveness and advanced tumor stage in 
prostate, gastric, colon and breast cancer [34–37]. In addition, EZH2 was shown to 
repress the Forkhead box transcription factor C1 (FOXC1), thereby enhancing 
breast cancer cell invasive potential [38]. EZH2 is also a crucial mediator of DNA 
damage response in cancer cells [39]. Thus, it may con-tribute to CSC chemo-
resistance. We think that future studies should specifically dissect the role of EZH2 
gene silencing in the CSC population.  
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Fig. 2. Mechanisms of Polycomb-dependent cancer progression. We showed some 
well-known mechanisms by which BMI1 and EZH2 trigger metastasis, chemo-resistance 
or cancer stem cell self-renewal. 
 
A consistent number of studies show that BMI1 is a proto-oncogene [40], which in 
several cases cooperates with EZH2. BMI1 was identified as a transcriptional 
repres-sor of specific genes, including the tumor suppressor p16 [41]. p16 is a cell 
cycle regulator whose activation leads to senescence and enhances 
chemosensitivity [11]. BMI1 over expression in lymphoma cells leads to a p16 
silenc-ing and to neoplastic transformation [41]. In addition BMI1 mediates chemo 
and radio-therapy resistance through its antioxidant roles in prostate [42] and head 
and neck tumors [43]. BMI1-controlled antioxidant genes were predictive of poor 
prognosis in aggressive prostate cancer patients, and should be tested as predictors 
of chemotherapy failure [42]. Moreover, through inhibition of the protein kinase B 
(AKT) pathway, BMI1 depletion enhanced the chemosensitivity of nasopharyngeal 
carcinoma cells [44]. Signal transduction pathways are able to modify PRC 
activity. In particular, the mitogen-activated protein kinase (MAPK) cascade leads 
to EZH2 over-expression in triple negative breast cancer [45]. Interestingly, EZH2 
promotes genomic instability in breast CSCs, leading to RAF (murine leukemia 
viral oncogene homolog) amplification and MAPK pathway activation [31]. On the 
other hand, protein kinase b (PKB) activation reduces PRC2 activity in cancer cells 
CSC self-renewal. 
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4.3 PcG: Prognostic and predictive role in human cancer 
 
Due to their role in CSC biology and tumor progression, PcGs are obvious 
candidates as novel prognostic and predictive markers. At present, most studies 
have been focused on the former aspect, somehow neglecting the latter. The 
identification of markers predicting response to a specific therapy is a complex 
task; indeed, it requires the comparison between patients treated with at least two 
equivalent regimens [47]. If the marker is a true predictive factor, it should be 
correlated to clinical outcome in a single treatment group. Another methodological 
challenge is how to analyze PcG activity. Most studies focused on mRNA and 
protein expression form primary tumors. An alternative approach is to look at 
specific histone modifications, mediated by PRCs. In Table 2, we summarized pre-
clinical and clinical data suggesting a prognostic role of PcG members in human 
cancers. The prognostic role of EZH2 in solid tumors has been first identified by 
Varambally et al. [48]. They found that EZH2 is highly expressed in metastatic 
prostate cancer and predicts poorer overall survival. Keeping with this evidence, an 
EZH2- dependent chromatin signature was shown to predict shorter relapse-free 
survival in breast and prostate cancer patients [49]. Glinsky and co-workers showed 
that EZH2 expression is essential for prostate cancer cells’ anchorage-independent 
growth and metastatization [50]. Thus, EZH2 seems to play a prominent role in 
prostate cancer metastatization, thereby affecting patient prognosis. In addition, 
EZH2 emerged as an interesting marker in gynecological malignancies. In normal 
breast tissue, EZH2 marks pre-cancerous lesions. In breast cancer, it is associated 
to poor differentiation [51], higher angiogenic potential [52] and shorter metastasis-
free survival [53]. EZH2 is also expressed by tumor-associated endothelial cells. A 
microarray study on tumor-associated cells form ovarian cancer samples showed 
that EZH2 was one of the most up-regulated genes in tumor vs. normal samples 
[54]. In addition, EZH2 silencing was able to abrogate neo-angiogenesis in vitro. If 
this evidence is confirmed, EZH2 inhibition could emerge as a novel anti-
angiogenic strategy. BMI1 and EZH2 share similar features in prostate cancer. 
High BMI1 expression is predictive of shorter relapse-free survival after 
prostatectomy [55]. In addition, both genes are required for prostate cancer cell 
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metastatic spreading [50] and epithelial-to-mesenchymal transition [56]. As shown 
in Table 2, both BMI1 and EZH2 generally emerged as poor prognostic factors in 
many cancer types, including colorectal, lung and brain tumors [57–73]. To the 
contrary, BMI1 up-regulation may be associated to longer overall survival in breast 
cancer patients [74]. Similarly, BMI1 seems to be a favorable prognostic indicator 
in melanoma [59]. These results indicate that PRCs may silence different set of 
genes in different tissues, and that their combinatorial complexity may generate 
unpredictable roles in specific cancer types. According to this paradigm, Wei et al. 
tested the hypothesis that histone H3 Lys 27 methylation predicts poorer prognosis 
in breast, ovarian and pancreatic cancers [70]. Surprisingly, they found that in all 
three cancer types high H3 Lys 27 methylation predicts longer overall survival, 
which is not associated to EZH2 levels. This results may be explained by the 
observation that histone H3 Lys 27 trimethylation is not exclusively dependent on 
EZH2 activity [75]. In agreement with this dual role, H3 Lys 27 trimethylation 
assayed in specific PcG-target loci was, on the other hand, predictive of poor 
prognosis in prostate cancer patients [49]. In the future, the specific prognostic role 
of PcG members should be addressed in each cancer type. PcG members other than 
EZH2 and BMI1 have been poorly investigated, and may shed new light on 
currently available data. In addition, most analyses are now performed on primary 
tumors, which are not often available in clinical setting. EZH2 is overexpressed in 
poorly differentiated CCA [76]. Several genetic and epigenetic factors may be 
involved in the deregulation and modulation of key signaling pathways in tumor 
aggressiveness and chemoresistance. The abnormal expression of EZH2 is involved 
in the tumorigenic processes and is regarded as a potential marker of aggressive 
types of cancer with poor prognoses [77,78]. Previous studies have demonstrated 
that EZH2 contributes to the epigenetic silencing of several target genes that 
control cell growth and proliferation, including E-cadherin, Rb and p16 [79]. The 
overexpression of EZH2 may induce hypermethylation of the promoter of the p16 
gene, reducing the expression of p16, which is a key step in the multistep 
cholangiocarcinogenesis from hepatolithiasis to intraepithelial neoplasia [80].  
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4.3.1 PcG Single Nucleotide Polymorphisms in human cancer  
 
The identification of easy-to-perform assays form blood samples could 
enhance our possibility to study the role of PcG genes in human tumors. 
In this regard, germinal polymorphic variants or dosage of tumor-
derived proteins from blood samples are promising tools. For example, 
26 single nucleotide polymorphisms (SNPs) have been described in the 
EZH2 locus [81]. Of these, 1 is associated to a missense mutation, while 
3 intronic SNPs may predict lung cancer risk. Thus far, the prognostic 
and predictive role of these SNPs in cancer patients has been 
investigated only in colorectal cancer. Interestingly, an EZH2. SNP has 
been correlated to higher mRNA expression, and shorter survival in 
metastatic colorectal cancer patients [82]. Mel18 (Polycomb group 
RING finger protein 2) is a PRC1 member, which acts with opposite 
functions with respect to BMI1 [83]. In prostate cancer, Mel18 is a 
tumor-suppressor gene, and high Mel18 expression is associate to longer 
survival. A SNP in the 3_-untranslated region was shown to affect 
Mel18 expression in prostate cancer, and clinical outcome after 
prostatectomy [84].  Single-nucleotide polymorphisms (SNPs) are easy-
to-detect genetic variants since they can be analyzed from blood 
samples [85]. Thus, they are attractive molecular markers for 
translational studies. Recently, EZH2 locus has been mapped for the 
presence of SNPs in normal individuals and lung cancer patients [86]. 
Three EZH2 SNPs were shown to predict lung cancer risk, while 
another was characterized as producing an aminoacidic change in the 
EZH2 protein.   
 
4.3.2 3’-Deazanepalnocin-A (DZNep)  a PRC2 inhibitor 
 
Epigenetic drugs have been largely tested in pre-clinical and clinical 
cancer models, with uneven outcomes. Currently, DNA 
methyltransferase- and histone deacetylase-inhibitors have been 
approved for the treatment of some hematological malignancies [87]. 
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However, the efficacy of epigenetic therapy in solid tumors still needs to 
be proved. This may be explained by the fact that solid tumor CSCs are 
confined to a niche that is less reachable by these drugs. In addition, 
epigenetic therapy may be ineffective if not combined with classical 
chemotherapy, like other “biological” drugs (e.g. VEGFR inhibitors). 
An alternative explanation is that DNA methylation and histone 
acetylation are not viable targets for solid tumor CSCs. Due to the role 
of PRCs in CSC biology and clinical features, they could emerge as 
promising therapy targets. At present, no specific inhibitor of PRC1 has 
been tested on cancer models. The S-adenosylhomocysteine hydrolase 
inhibitor, 3-Deazaneplanocin A (DZNeP), was shown to inhibit H3 Lys 
27 methylation and EZH2 expression in sev- eral cancer cell lines [88]. 
Interestingly, DZNeP induced apoptotic cell death in cancer cells but 
not in normal cells. DZNeP treatment was able to reactivate a set of 
PRC2 target genes, including the apoptotic effector FBXO32 (F-box 
pro-tein 32), thus triggering cell death. At present, DZNeP activity has 
been tested on breast, colorectal, hepatoma, prostate, lung and brain 
cancer cell lines [32,88–90]. Puppe et al. [89] showed that BRCA1-
deficient breast cancers, which are associated to poorer prognosis, over-
express EZH2. In addition, DZNeP is 20-fold more effective in killing 
BRCA1- deficient that BRCA1-proficient cells. Thus, DZNeP may be 
employed to treat this particular breast cancer subtype, which is 
generally less differentiated and more stem-like. DZNeP was directly 
tested as an anti-CSC drug on glioblas-toma and prostate cancer models 
[32,91]. Interestingly, it was able to abrogate CSC self-renewal in vitro 
and tumorigenicity in vivo. Due to the role of EZH2 in epithelial-to-
mesenchymal transition and metastatic spreading [50,92], it would be 
inter- esting to test this drug as an anti-metastatic agent, particularly in 
breast and prostate cancer models. Despite these promising results, 
DZNeP was shown to be a non-specific inhibitor of histone methylation, 
with addi-tional effects on many PRC2-independent modifications [93]. 
This may result in the activation of genes promoting tumor growth, or in 
the inactivation of tumor suppressor genes [94]. Thus, the development 
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of more specific PRC2 inhibitors is warranted. In addition, the 
pharmacokinetic and toxicolog-ical profile of DZNeP in humans needs 
to be addressed. In particular, DZNeP did not show any obvious toxicity 
when administered as a 10 mg/kg single dose [95]. This data are 
encouraging, since DZNeP showed in vivo antitumor activity at 1 mg/kg 
dose [96]. However, specific toxicological profiles of different doses 
and regimens should be investigated in future studies. Despite its 
promising activity in glioblastoma models, DZNeP is highly water 
soluble, hydrophilic drug with a negative partition coefficient (log P = 
−1.38), a feature that makes it difficult for the drug to cross the blood–
brain-barrier. Therefore, the development of more lipophilic pro-drugs 
congeners, such as alkyl esters of DZNep, is warranted.  
 
4.4 BMI-1 and Mel-18: The controversial role in different Breast Cancer sub-types 
 
4.4.1 BMI-1 collaborates with c-Myc and H-Ras in tumor aggressiveness 
 
C-myc is a DNA-binding, nuclear transcription factor involved in the 
regulation of the cell cycle, programmed cell death, and tumorigenesis. 
C-myc was first detected in Burkitt’s lymphoma, but has later been 
connected with many other cancers, including breast and colon cancer. 
C-myc is often associated with poor prognosis, indicating a key role for 
this oncogene in tumor progression [97]. Myc gene amplification has 
been associated with high histological grade, the presence of lymph 
node metastasis, a lack of progesterone receptor, and poor survival in 
breast cancer [98]. Studies show that breast cancer patients with c-myc 
ampliﬁcation have a shorter relapse-free survival, especially those with 
node negative and receptor-positive tumors [99]. Bmi-1 influences c-
myc activity and vice versa, BMI1 was first identified as a Myc-
cooperating oncogene in murine B and T-cell lymphomas [100-101]. 
BMI1 collaborates with the myc gene in tumor development [101]. 
Mouse xenograft studies indicate that coexpression of Bmi-1 and H-Ras 
in breast cancer cells can induce an aggressive and metastatic phenotype 
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with an unusual occurrence of brain metastasis; although, BMI1 
overexpression did not result in oncogenic transformation of MCF10A 
cells [102]. Hoenerhoff et al demonstrate that overexpression of BMI1 
in MCF10A cells overexpressing H-Ras results in a marked spindle-type 
change in cell morphology, increased proliferation, increased invasive 
properties and resistance to apoptosis in vitro, and spontaneous 
metastatic disease in mice with the extremely unusual dissemination of 
metastases to the brain [103]). In previous studies they showed that 
BMI1 collaborates with H-Ras to induce transformation of MCF10A 
human mammary epithelial cells through dysregulation of multiple 
growth pathways independent of the INK4A/ARF locus [103]. 
Furthermore, in collaboration with H-Ras, BMI1 induced fulminant 
metastatic disease in the lung using a tail vein model of haematogenous 
spread through accelerated cellular proliferation and inhibition of 
apoptosis. Finally, they show that knockdown of BMI1 in several 
established breast cancer cell lines leads to decreased oncogenic 
behaviour in vitro and in vivo. The suppression of p16Ink4a occurred in 
parallel with an increase in Bmi-1 and/or p16Ink4a promoter 
hypermethylation. Consistent with these observations, the H-Ras-
stimulated induction of p16Ink4a was suppressed significantly through 
the coexpression of Bmi-1 in vitro [104].  
 
4.4.2 Mel-18 in Triple Negative Breast Cancer  
 
Recent evidence indicates that breast cancer is a tumor generated by a 
small percentage of cancer stem cells (CSC). CSCs are responsible for 
resistance to hormonal therapy, chemotherapy, and metastatic 
progression. Polycomb group genes (PcG) mediate silencing of several 
tumor suppressor genes, and are essential for the survival of mammary 
CSC [105]. The expression of EZH2 and BMI1 has been related to a 
worse prognosis in patients with breast cancer [105]. Thus, complexes 
containing EZH2 and BMI1 favor the proliferation of mammary CSC 
acting as oncogenes in cancer. In contrast, the gene Mel-18 is a member 
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of PcG with onco-suppressive functions. Mel-18 competes with BMI1 
becoming a part of the polycomb repressive complex 1 (PRC1), acting 
in an opposite way to this oncogene. For example, BMI1 is involved in 
the silencing of genes that induce senescence (p16) and activates the 
signal transduction pathway-dependent protein kinase Akt [106]. 
Overexpression of Mel-18 in breast cancer cells blocks the proliferation, 
reactivating p16 and inhibiting Akt. Mel-18 has recently emerged as an 
inhibitor of tumor angiogenesis, a process critical to tumor progression 
[107]. In agreement with these data, Mel-18 expression is low in breast 
cancer and in particular in TNBC, compared to non-tumor tissue, and its 
expression decreases progressively in tumors of higher stage [108]. 
Recently, a germ line polymorphism of Mel-18 has been described and 
studied in patients with prostate cancer (1805 A / G). Patients with 
genotype G / G (about 15% of the population) have a lower expression 
of Mel-18 gene, and a worse prognosis in terms of time to progression 
after prostatectomy [109]. The authors speculate that the polymorphism 
influences gene expression through modulation of the link between 
mRNA of Mel-18 and the miRNA181a. This hypothesis has not been 
confirmed by experimental data. The TNBC is a particularly aggressive 
tumor with a gene expression profile similar to that of  CSC. From an 
analysis of genomic expression, it was found that patients with TNBC 
have hyper-activation of genes with Polycomb function of oncogenes 
(EZH2 and BMI-1). A meta-analysis by our database Oncomine 
(www.Oncomine.com) showed that Mel-18 is significantly low  in 
TNBC, compared to other histologies, and that a reduced expression of 
Mel-18 is associated with a higher probability of recurrence after 
mastectomy. The TNBC seem therefore characterized by the activation 
of oncogenes Polycomb complexes (EZH2 and BMI-1) and the 
inhibition of tumor suppressor complex (containing Mel-18). Therefore 
is possible that the gene Mel-18 might influence the development and 
prognosis of TNBC.  
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5. Objectives of the thesis 
 
5.1 Objective of the first study:     Moving from the hypothesis that polymorphic 
variants of such a key determinant as EZH2 gene of the biology of CSCs may 
affect clinical outcome, we aimed at investigating the role of  EZH2 SNPs 
among mCRC patients treated with first-line FOLFIRI plus bevacizumab and 
CCA patients. 
 
5.2 Objective of the second study:    
 
Ougolkov and colleagues showed that EZH2 is an important factor in PDAC 
cell chemoresistance. In particular, EZH2 depletion by RNA interference 
sensitized PDAC cells to gemcitabine, which is used in the first-line treatment 
for PDAC. Since gemcitabine has very limited efficacy, novel therapeutic 
strategies combining gemcitabine with targeted agents against EZH2 are 
warranted. In keeping with this observation we aimed to evaluated the EZH2 
expression in PDAC tissues and cells, and the growth inhibition by DZNeP in 
combination with gemcitabine in monolayer cell cultures and cells growing as 
spheroids in serum-free CSC-medium. Furthermore, we characterized several 
factors, including cell cycle perturbation, apoptosis induction and inhibition of 
cell migration as well as modulation of the expression of several genes involved 
in the DZNeP/gemcitabine interaction. We evaluated a correlation between 
EZH2 SNPs and clinical outcome in CCA patients.  
 
5.3  Objective of the third study: Functional analysis of BMI-1 and Mel-18 in 
breast cancer cell lines including TNBC. Mel18 expression will modulate tumor 
aggressiveness and inhibit metastases in breast cancer 
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6. Methods 
 
6.1 Metastatic colorectal cancer patients and methods 
 
Oncomine analysis 
Oncomine 4.4 [1] collects gene expression data from cancer patients. This 
database was interrogated to investigate significant overlaps between two 
concepts: ‘Activated upon Polycomb Group knockdown’ [2] and ‘Patient 
Treatment Response’ in CRC (threshold: P < 0.01; odds ratio > 2.0)  
 
Patient selection and study treatment 
We retrospectively examined patients with histologically confirmed metastatic 
colorectal adenocarcinoma receiving first-line FOLFIRI [irinotecan 180 mg/m2 
i.v. day 1, leucovorin 200 mg/m2 i.v. day 1 and 5-fluorouracil (5-FU) 400 
mg/m2 bolus i.v. day 1 followed by 5-FU 2400 mg/m2 46-h continuous 
infusion (ci) i.v. days 1/3 or 5-FU 3200 mg/m2 48-h ci i.v. days 1/3 without 
bolus administration] plus bevacizumab (5 mg/kg i.v. over 30 min on day 1; 
repeated every 2 weeks). Patients were considered eligible for inclusion into the 
study if they had received an actual dose intensity of 5-FU and irinotecan of at 
least 85% of the projected dose intensity. Pretreatment evaluation included 
medical history, physical examination and assessment of performance status. 
Complete blood cell count with differential, routine chemistry, liver and kidney 
function tests, carcinoembryonic antigen analysis and a computed tomography 
scan of the chest and abdomen were carried out before treatment start and every 
2 months until evidence of disease progression. 
 
Evaluation of activity and efficacy 
Objective response assessment was carried out according to RECIST [3]. The 
assessment of response and progression was based on investigator-reported 
measurements. All patients with measurable lesions were evaluated for 
response, while all genotyped patients were included in the progression-free 
survival (PFS) and OS analyses. PFS was defined as the time from the date of 
treatment start until the evidence of disease progression or death from any 
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cause, whichever occurred first. Patients who underwent secondary radical 
surgery on metastases were censored at the time of surgery. OS was defined as 
the time from the date of treatment start until death from any cause. 
 
Sample collection and DNA and RNA isolation 
Peripheral venous blood samples from an antecubital vein of 110 mCRC 
patients treated with first-line FOLFIRI plus bevacizumab were collected 
before treatment start and stored in anonymity at 22°C in the Laboratory of 
Pharmacology (Department of Internal Medicine, University of Pisa, Italy) until 
molecular analyses were carried out. The study was conducted in accordance to 
the Declaration of Helsinki and Good Clinical Practice guidelines and the 
protocol was approved by the Ethics Committee of Pisa University Hospital. 
Patients were informed of the investigational nature of the study and provided 
their written informed consent before registration on to the study. DNA 
analyses were carried out by investigators who were blinded to clinical data. 
Genomic DNA was isolated using the QIAamp DNA Mini Kit (Qiagen). The 
purity and quantity of DNA obtained was measured by Uvikon-940 
spectrophotometer (Kontron). DNA and RNA were extracted from peripheral 
blood lymphocytes of 50 consecutive radically resected stage II or III CRC 
patients, as previously described. Blood samples were collected before the start 
of adjuvant treatment. RNA was retrotranscribed, as described in [4]. 
                   
                  SNP genotyping and EZH2 mRNA expression 
EZH2 SNPs [c.553G>C (rs2302427); c.2110+6A>C (rs41277434); c.626-
394C>T (rs3757441); g.91772121T>C (rs6958683)] were analyzed through 
real-time PCR. Target SNPs were studied with TaqMan probe-based assays 
using the PCR real-time ABI PRISM 7900HT instrument equipped with the 
Sequence Detection System version 2.0 software (Applied Biosystems, 
Carlsbad, CA). Assay IDs were C__15757626_10 (rs2302427) and 
C___326857_10 (rs3757441). The remaining SNP assays were designed 
through File-Builder software (Applied Biosystems). The PCR reactions were 
done using 20 ng of genomic DNA diluted in 11.875 ll DNase/RNasefree water, 
12.5 ll of TaqMan Universal PCR Master Mix with AmpliTaq Gold and 0.625 
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ll of the assay mix (forward- and reverse-specific primers and the specific 
probes), in 25 ll. Applied Biosystems SNP genotyping assays were used for 
genotyping. The allelic content of each sample was determined by reading the 
generated fluorescence. After retrotranscription, complementary DNA from a 
parallel cohort of 50 CRC patients was used to measure EZH2 expression, 
using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as reference gene. 
Applied Biosystems gene expression assay numbers were 4326317 (GAPDH) 
and Hs01016789_m1* (EZH2). Figure 2 shows 2DCt values, normalized to the 
lowest EZH2 expression level. 
 
Statistical analysis 
This retrospective analysis aimed at evaluating the relation of EZH2 
polymorphisms with outcome parameters such as response rate (RR), PFS and 
OS. All polymorphisms were examined for deviation from Hardy–Weinberg 
equilibrium [5] by comparing actual allelic distributions with those expected 
using a chi-square test. A chi-square test for trend was used to evaluate the 
association of investigated EZH2 SNPs with response. PFS and OS were 
determined using the Kaplan–Meier method and compared according to EZH2 
SNP variants using the log-rank test. Statistical significance was set at P < 0.05 
for a twotailed test. Statistical analyses were done using GraphPad Prism 
(version 5). We used a Cox model to evaluate the effect of 626-394C>T and 
prognostic factors on PFS and OS, using the survival library of the R package 
[Terry Therneau and original R port by Thomas Lumley (2009)]. Survival: 
survival analysis, including penalized likelihood. R package version 2.35-7. 
http://CRAN.R-project.org/package=survival.). 
 
In silico characterization of 626-394C>T SNP 
To evaluate transcription factor (TF) binding affinity of the C and T allele, we 
used PROMO3.0 software (http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3).  We considered human 
factors and human binding sites, with a maximum matrix dissimilarity rate of 
15. DNA sequence was downloaded from ‘Entrez SNP’ 
(http://www.ncbi.nlm.nih.gov/snp). Using the same DNA sequence, we tested 
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the hypothesis that this SNP may affect the creation of a new splice variant in 
exons 6 and 7. For this purpose, we employed the National Center for 
Biotechnology Information (NCBI) Aceview database 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human&l=EZ
H2).  
 
6.2 Pancreatic cancer material and methods 
 
Drugs and chemicals 
DZNeP was provided by Dr. Victor E. Marquez (NCI, NIH, Frederick, MD), 
while gemcitabine was a gift from Eli Lilly Corporation (Indianapolis, IN). The 
drugs were dissolved in sterile water, and diluted in culture medium before use. 
RPMI medium, foetal bovine serum (FBS), penicillin (50 IU/ml) and 
streptomycin (50 µg/ml) were from Gibco (Gaithersburg, MD). All other 
chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
 
Cell culture 
Eight PDAC cell lines (PANC-1, MIA-PaCa-2, BxPc3, Capan-1, PL45, HPAC, 
HPAF-II, and CFPAC-1), the human pancreatic duct epithelial-like cell line 
hTERT-HPNE and skin fibroblasts Hs27 were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA), while seven primary PDAC 
cultures (LPc006, LPc028, LPc033, LPc067, LPc111, LPc167 and PP437) were 
isolated from patients at the University Hospital of Pisa (Pisa, Italy), as 
described previously (18). Cells were cultured in RPMI-1640, supplemented 
with 10% heat-inactivated- FBS and 1% streptomycin/penicillin at 37°C, and 
harvested with trypsin-EDTA in their exponentially growing phase. The cell 
lines were tested for their authentication by PCR profiling. 
 
Quantitative Real-Time PCR 
Total RNA was extracted using the TRIREAGENT-LS (Invitrogen, Carlsbad, 
CA, US) and its yields and purity were checked at 260-280 nm with 
NanoDrop®-1000-Detector (NanoDrop- Technologies, Wilmington, NC). In 
order to prevent RNA degradation, the cells were harvested quickly on ice. One 
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µg of RNA was reverse transcribed using the DyNAmo-cDNA-Synthesis Kit 
(ThermoScientific, Vantaa, Finland), according to the manufacturers’ 
instruction. In order to evaluate whether the expression of EZH2 was similar in 
the primary cells and their originator tumors, we also extracted RNA from these 
7 tumors, after laser-microdissection with a Leica- LMD6000 instrument 
(Leica, Wetzlar, Germany), using the QiaAmp-RNA-micro-Kit (Qiagen, San 
Diego, CA), as described previously [6]. Primers and probes to specifically 
amplify EZH2, hENT1, CD133, and E-cadherin (Hs01016789_m1, 
Hs00191940_m1, Hs01009250_m1, and Hs01023894_m1, respectively) were 
obtained from Applied Biosystems (Forster City, CA). The real-time 
quantitative PCR reactions were performed in the ABIPRISM-7500 sequence 
detection system instrument (Applied Biosystems). We performed a 
preliminary analysis of 3 housekeeping genes (β-actin, GAPDH and Beta-2-
microglobulin) in all our PDAC cells. Since the values of β-actin were the 
closest to the geometric mean values of these housekeeping genes, we used this 
housekeeping for the normalization of all the following analysis. Preliminary 
experiments were carried to demonstrate that the efficiencies of amplification of 
target and reference genes are approximately equal [6]. 
 
Western blot 
In order to evaluate modulation of EZH2 and H3K27me3 protein expression, 
the PANC-1, MIAPaCa-2, and LPC006 cells were treated with 5 µM DZNeP 
for 72 hours, as reported [7]. Blotting procedures were performed as described 
previously [6]. Membranes were incubated overnight at 4°C with purified 
mouse anti-EZH2 mAb (BD Biosciences, Breda, The Netherlands) at 1:1000 
dilution in blocking solution (Rockland in PBS-T), rabbit anti-H3K27me3 
(1:1000; Upstate Biotechnology, Waltham, MA), rabbit anti-hENT1 and rabbit 
antihCNT1 (1:1000, kindly provided by Prof. M. Pastor-Anglada), and mouse 
anti-β-actin (1:50.000; Sigma–Aldrich Chemicals). The membrane was then 
probed for 1-hour with the goat antimouse-InfraRedDye (1:10.000, Westburg, 
The Netherlands) or goat-anti-rabbit-InfraRedDye 
(1:10.000, Westburg) secondary antibodies. Fluorescent proteins were detected 
by an Odyssey Infrared Imager (LI-COR Biosciences, Lincoln, NE), at 84-µm 
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resolution, 0-mm offset, using high quality settings. Then, the intensities of 
protein bands were quantified using the Odyssey v.3.0 software (LI-COR, 
Bioscience). 
 
Immunocytochemistry 
The LPc006 cells were grown in Chamber Slides System (Lab-Tek, Chicago, 
IL) in a humidified incubator. After 48 hours the cells were fixed with 70% 
ethanol for 10 minutes. Immunocytochemistry was performed using a 
monoclonal mouse-anti-human E-cadherin antibody (Cell Signaling, Euroclone, 
Milan, Italy; 4°C overnight incubation and 1:30 dilution in PBS). Cells were 
then stained with avidin-biotin-peroxidase complex (UltramarqueTM-
HRPDetection, Greenwood, AR). Negative controls were obtained replacing 
the primary antibody with PBS. The sections were reviewed and scored blindly 
by comparing the staining of treated cells versus untreated cells (positive 
control, basal expression), using a system based on staining intensity and on the 
number of positively stained cells, as described [6]. 
 
Growth inhibition studies 
Cell growth inhibitory effects of the DZNeP, gemcitabine and their 
combination were studied using the sulforhodamine-B (SRB) assay. Cells were 
seeded in triplicate at 5x103 cells/well and kept at 37°C for 24 hours. Then the 
cells were treated for 72 hours with DZNeP (0.001-20 µM), gemcitabine 
(0.001-500 nM) and DZNeP at fixed concentration of 5 µM simultaneously 
with gemcitabine (0.001-500 nM). After 72 hours, plates were processed for the 
SRB assay as described earlier [8]. In order to determine whether the drug 
could kill cells, we also measured Optical Density (OD) of the day of drug 
addition, since cell kill could lead to a decrease in the OD of day 0. Therefore, 
for the cell growth inhibition curves, the OD after 72 hours was corrected for 
the mean OD observed for the control wells at the day of drug addition (day 0 
value). The 50% growth inhibitory concentration (IC50) was calculated by non-
linear least squares curve fitting (GraphPad PRISM, Intuitive Software for 
Science, San Diego, CA). 
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Evaluation of synergistic/antagonistic interaction of DZNeP with gemcitabine 
The drug interaction of DZNeP and gemcitabine was evaluated by the median-
drug effect analysis method originally described by Chou [9]. Cell growth 
inhibition of the combination was compared with the cell growth inhibition of 
each drug alone using the combination index (CI), where CI<0.9, CI=0.9-1.1, 
and CI>1.1 indicated synergistic, additive and antagonistic effects, respectively. 
Data analysis was carried out using CalcuSyn software (Biosoft, Oxford, UK). 
Since we considered growth inhibition lower than 50% as not relevant, CI 
values at fraction affected (FA) of 0.5, 0.75 and 0.9 were averaged for each 
experiment, and this value was used to calculate the mean between 
experiments. 
 
Cell-cycle analysis and measurement of cell death 
Cell-cycle modulation and cell death induced by treatments with 5 µM DZNeP, 
gemcitabine at IC50 values and their combination was investigated using 105 
cells, after 24 and 72 hours, by Propidium Iodide (PI) staining using a 
FACScaliber flow-cytometer (Becton-Dickinson, San Jose´, CA). Data analysis 
was carried out with CELLQuest (Becton-Dickinson), while cell cycle 
distribution was determined using Modfit (Verity-Software, Topsham, ME), as 
described [10]. DZNeP, gemcitabine and their combination were also 
characterized for their ability to induce cell death, by evaluating the sub-G1 
region of the FACS analysis [11], and by fluorescence microscopy analysis 
with bisbenzimide staining [10]. 
 
In vitro migration assay (Wound-healing assay) 
Migration was evaluated using the LeicaDMI300B (Leica) migration station 
integrated with the Scratch-Assay 6.1 software (Digital-Cell Imaging Labs, 
Keerbergen, Belgium). Briefly, cells were plated at a density of 3x104 
cells/well onto 96-well plates, and, after 24 hours, artificial wound tracks were 
created by scraping with a specific scratcher within the confluent monolayers. 
After removal of the detached cells by gently washing with PBS, the cells were 
fed with fresh medium and exposed to 5 µM DZNeP, gemcitabine at IC50, or 
their combination. The ability of the cells to migrate into the wound area was 
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assessed by comparing the pixels in the images taken at the beginning of the 
exposure (time 0), with those taken after 4, 6, 8, 24 and 48 hours. 
 
DZNeP/Gemcitabine activity in multicellular spheroids 
PANC-1, MIA-PaCa-2 and LPc006 spheroids were established seeding 10000 
cells/ml in DMEM/F12+GlutaMAX-I (1:1) with insulin-transferrin-selenium 
(1:1000, Gibco, Invitrogen), in 24-well ultra-low attachment plates (Corning, 
NY, US), according to manufacturers’ protocol, as described earlier [12]. 
Spheroids were generated for 10-14 days, and then harvested for growth 
inhibition studies in 96-well plates, as well as for RNA isolation. After 
checking their growth rate and stability, the spheroids were treated with 5 µM 
of DZNeP, IC50s of gemcitabine and their combination for 72 hours. The 
cytotoxic effects were evaluated by measuring the size and number of spheroids 
with the microscope LeicaDMI300B (Leica), taking 9 pictures for each well. 
Spheroid volume (V) was calculated from the geometric mean of the 
perpendicular diameters D=(Dmax+Dmin)/2, (V=4/3π(D/2)3). 
 
Liquid chromatography–mass spectrometry (LC-MS/MS) measurement of 
adenosine and phosphorylated deoxynucleosides 
Analysis by LC-MS/MS was used to determine total cytosolic adenosine as 
well as total phosphorylated deoxynucleosides. The latter were calculated from 
the difference before and after alkaline phosphatase treatment, as described 
previously [13]. Approximately 2×106 cells were seeded into 6-well plates, and 
exposed to either 5 µM DZNeP, gemcitabine at IC50 values, or 
DZNeP/gemcitabine combination for 24 hours, prior to being snap frozen as a 
pellet. Cell pellets were re-suspended in a known aliquot of phosphate buffer 
and precipitated with excess isopropyl alcohol. The supernatant was removed 
and evaporated to dryness via freeze-drying. The dry samples were 
reconstituted in 200 µl of water and 20 µl aliquots were used for analysis. The 
remaining samples were treated quantitatively with alkaline phosphatase (4 
units) at 37°C overnight. Chromatography was conducted using a Dionex 
Ultimate 3000 micro HPLC coupled via a Turbo spray ionization source to a 
SCIEX API 3000 mass spectrometer (Applied). Data analysis was performed 
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with v.1.52 Analyst software (AB Sciex, Nieuwerkerk aan den Ijssel, 
Netherlands) controlled by Dionex Mass Spectrometry Link combined with 
Chromeleon management software modules (Thermo Scientific). 
 
Statistical analysis 
All experiments were performed in triplicate and repeated at least twice. Data 
were expressed as mean values±S.E. and analysed by Student’s t-test or 
ANOVA followed by the Tukey's multiple comparison test. The level of 
significance was P<0.05. 
 
6.3 Cholangiocarcinoma patients and methods 
 
Patients  
A total of 75 patients with histologically confirmed unresectable biliary tract 
cancer were enrolled in this retrospective pharmacogenetic single-center study 
at the Department of Oncology of Carrara Civic Hospital (Carrara, Italy), 
between February 2004 and November 2010. CCA patients were treated 
upfront with intravenous or intra-arterial cisplatin (Platinol®, Bristol-Myers 
Squibb, Roma, Italy) and epirubicin (Pharmorubicin®, Pfizer Italia S.R.L., 
Latina, Italy) and oral capecitabine (Xeloda®, Roche S.p.A, Milano, Italy; ECX 
regimen). This study was approved by the ethics review board of Carrara 
Hospital. Informed consent was obtained from all the patients. 
 
DNA isolation 
 Genomic DNA was extracted from peripheral venous blood samples (5 ml) 
from an antecubital vein of 75 CCA patients and stored anonymously at -20˚C 
in the Laboratory of VU University Medical Center, Department of Medical 
Oncology (Amsterdam, The Netherlands). Genomic DNA was isolated through 
the QIAamp DNA mini kit (Qiagen, Venlo, The Netherlands). The purity and 
quantity of DNA obtained were measured by spectrophotometer 
NanoDrop®1000 Detector (NanoDrop-Technologies, Wilmington, DE, USA). 
The absorbance was read at 260 and 280 nm and the contamination by proteins 
was estimated through the calculation of 260/280 ratio. 
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In silico analysis 
A total of 26 previously described EZH2 SNPs were functionally tested by the 
appropriate software. SNPs were screened through in silico characterization 
based on functional relevance [missense mutation, transcription factor binding 
(TFB), miRNA binding]. In particular, the PROMO3.0 
(http://alggen.lsi.upc.es/cgibin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3)  
in which human factors and binding sites were considered, with a maximum 
matrix dissimilarity rate of 15 (21,22), GeneCard (http://www.genecards.org/) 
and MicroSNiper (http://cbdb.nimh.nih.gov/microsniper) software were used. 
 
SNP genotyping 
 EZH2 SNPs g.148525904C>G (rs2302427), g.148519011C>T (rs6464926), 
g.148517456T>G (rs17171119) and g.148505302 C>T (rs887569) were 
analyzed with real-time PCR. Applied Biosystems SNP genotyping assays were 
used for reactions. The PCR assays were performed using 20 ng of genomic 
DNA diluted in 5.94 µl DNase RNase free water, 6.25 µl of TaqMan Universal 
Master Mix (Applied Biosystems, Foster City, CA, USA) with AmpliTaq Gold 
and 0.3125 µl of the assay mix (specific primers and probe) in 12.5 µl total 
volume. The allelic content of each sample in the plate was determined by 
reading the generated fluorescence. 
 
Statistical analysis 
All SNPs were examined for Hardy-Weinberg equilibrium [14]. Overall 
survival (OS) and time to progression (TTP) curves were obtained through the 
Kaplan-Meier method and the log rank test was used to compare the survival 
distributions. P<0.05 was considered to indicate a statistically significant result. 
The Cox regression model was used to test the effect of g.148505302 C>T SNP 
and prognostic factors on OS. 
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6.4 Breast Cancer in vitro and in vivo Methods 
 
Breast Cancer Cell Culture 
Human epithelial cell line (MCF10A) and human breast cancer cell lines MDA-
MB-231, Hs578T, SUM 159, HCC38, BT-549, MCF-7, BT-20, BT-474, MDA-
MB-453, SKBR3, T47D and ZR751 were purchased from the American Type 
Culture Collection (USA). Growth media for BT-549, BT-474, HCC38, T47D 
and ZR751 cells (RPMI medium 1640), MDA-MB-231, Hs578T, MCF-7, BT-
20 and MDA-MB-453 cells [(D) MEM], SKBR3 (McCoy’s 5A) were 
supplemented with 10% (v/v) fetal bovine serum (FBS) and penicillin-
streptomycin. MCF10A cells and the derivative cell lines MCF10A, 
MCF10A+BMI-1, MCF10A+Ras, MCF10A+BMI-1+Ras (REFERENCE) were 
cultured in (D)MEM/F12 supplemented with 5% horse serum (HS), 1% 
penicillin-streptomycin,  20 ng/ml epidermal growth factor (EGF), 0.5 ug/ml 
hydrocortisone, 100 ng/ml Cholera toxin and 10 ug /ml insulin. SUM 159 cells 
were cultured in Ham's F-12 medium supplemented with 10% FBS.  
 
Vectors and Viruses: Bmi-1 and H-Ras overexpression 
Construction of the pBabe-puro retroviral vectors (pB0) expressing human 
Bmi1 or H-Ras and the generation of retrovirus was previously described  [15].  
Virus-containing supernatants were centrifuged to remove cell debris and stored 
at −70°C. pB0 control or pB-Bmi-1 and pB-hRas retroviral supernatants were 
rapidly thawed at 37°C and used to infect MCF10A cells for three sequential 
infections, each for 4 h, in the presence of Polybrene (4 µg/ml). pB-BMI-1 
virally transduced cells were selected in 0.5 µg/ml puromycin for 3–5 days, pB-
H-Ras virally transduced cells were selected in 50 µg/ml. This protocol 
typically yielded 60–80% infection efficiency. Cells were passaged every 3-4 
days.  
 
Mel-18 overexpression 
Human Mel-18 was cloned into the BamHI & EcoRI sites, the vector has 
puromycin as the selection marker for cell culture and ampicillin for growth in 
bacteria. It was amplified by the The PureYield™ Plasmid Maxiprep System. 
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WT (empty vector) and pLPC Mel-18 cDNAs were transfected with 
Lipofectamine™ 2000 in 293T cell line. Virus-containing supernatants were 
centrifuged to remove cell debris and used to infect breast cancer cell lines 
(MDA-MB-231 and BT-474) in the presence of 0.5 µg/ml  puromycin with 
selection for 5-7 days. Cells were passaged every 3-4 days.  
 
shRNA transfections: Mel-18 Knock down 
Transfections were performed by pre-complexing shRNAs with Polybren  (4 
µg/ml) in serum-free media in individual wells. Spinoculation was performed 
for 60 minutes at 1000 rpm at room temperature (RT) (ref). The cell/shRNA 
mixure was placed in a humidified atmosphere containing 5% CO2 at 37 °C for 
24 hours. Cells were passaged every 3-4 days and treated with 4 µg/ml 
blasticidin S HCl for 10-14 days.  RNA for quantitative real-time PCR was 
isolated from 6 well plates 14 days post-transfection (see below). 
 
mRNA gene expression analysis: Quantitative reverse transcription PCR (Q-
RT-PCR) 
RNA was extracted from cells using TRIzol reagent (Invitrogen) and purified 
using the RNeasy Mini kit (Qiagen) according to the manufacturer's 
instructions. cDNA was synthesized from 1 µg of total RNA using the 
Superscript III kit (Life Technologies). Q-RT-PCR was performed using IQ 
SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) and an iCycler 
Thermal Cycler (Bio-Rad Laboratories) and using TaqMan reverse transcription 
reagents (Applied Biosystems, Carlsbad, CA). The quantity of mRNA was 
normalized to the housekeeping gene GAPDH. 
 
Western Blotting, Antibodies  
Cells were lysed in ice-cold RIPA buffer for western blot analyses as described 
previously [15]. Denatured protein lysates (40 µg) in Laemmli loading buffer 
were analyzed by gradient (4–15%) SDS-PAGE and western blotting. Western 
blots were probed with antibodies for α-tubulin (CP06, Calbiochem, 
Cambridge, MA),  Mel-18 , CK8, CK14, Vimentin, LOXL2 (H-115, Santa Cruz 
Biotechnology, Santa Cruz, CA) and Twist (ab50887, Abcam, Cambridge, 
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MA),. BMI-1 (ab5856) , EZH2 (ab5246) , Snail (3895), E-cadherin (4065),  
Slug (9585), PARP (ab9532), Caspase-3 (ab9664) antibodies were purchased 
from Cell Signaling Technology (Danvers, MA).  
 
Proliferation Assay 
Cells were counted and plated in 96-well cell culture plates. At time points 
indicated, cell proliferation was assayed with CellTiter 96R Aqueous Non-
Radioactive Cell Proliferation Assay Kit following the manufacturer’s protocol 
(Promega, Madison, WI, USA). Data points represent an average of three 
samples per treatment and experiments were repeated at least three times. 
 
Apoptosis assay 
 Apoptosis was measured following treatment of each cell line with 100 mM 
etoposide after 12 and 24 hr for MCF10A-derived cell lines, and after 48 hr for 
shRNA expressing or vector control cell lines. After that we evaluated the 
Caspase-3 and PARP cleavage. 
 
Migration Assay 
Migration assays were performed with a cell migration assay kit (BDBio-coat). 
5 × 10
5
 Cells suspended in their own serum free media were placed in the upper 
compartment of each chamber. Lower compartments were filled with their own 
Media with 10% FBS. After 24 h, cells that had penetrated the matrigel-coated 
membrane and passed into the lower compartment were fixed and counted. 
 
Invasion Assay 
Invasion assays were performed with a cell invasion assay kit (BD Bio-coat). 
For confirmatory assays, we coated individual 12-µm pore transwell inserts 
with 50 µg of Matrigel (Becton Dickinson).  5 × 10
5
 cells suspended in serum 
free media were placed in the upper compartment of each chamber. Lower 
compartments were filled with Medium 10% FBS. After 24 h, cells that had 
penetrated the matrigel-coated membrane and passed into the lower 
compartment were fixed and counted. Later, the invasion assay was normalized 
to the same cell’s migration. 
53 
 
 
Oncomine Analysis 
In vitro data on Mel-18 silencing were compared with breast cancer expression 
profiles derived from the Oncomine 4.2 database analysis tool 
(http://www.oncomine.org). We selected studies based on a correlation 
coefficient higher than 0.5 (p-value=0.05). 
 
Statistical analyses  
Mean differences were tested with an unpaired Student's t-test. Statistical 
significance was depicted in the figures as *P<0.05, **p<0.01 and ***p<0.001. 
All in vitro experiments were repeated at least 3 times. 
 
In vivo  studies: necropsy and histopatology 
Animal studies were approved and performed in accordance with the National 
Institutes of Health Intramural Animal Care and Use Program. Cohorts of 8 six-
week-old female SCID mice (NCI Frederick, MD) were injected in the right 
axillary mammary fat pad with 1×106 cells (Cohorts: 1= MCF10Actrl; 
2=MCF10A-shMel18; 3=MCF10A+BMI1ctrl; 4=MCF10A+BMI1-shMel18; 
5=MCF10A+hRas-ctrl; 6=MCF10A+hRas-ShMel18; 
7=MCF10A+BMI1+hRas-ctrl; 8=MCF10A+BMI1+hRas shMel18). Tumour 
growth was measured weekly by calliper. Mice were followed for nine weeks. 
Mice were euthanized once tumors reached 2 cm in diameter, or when mice 
became clinically ill. Following euthanasia of mice that had received 
intramammary fat pad cell injections, tumour, brain, lung, heart, liver and 
spleen were collected, and fixed in 4% paraformaldehyde (PFA), processed into 
paraffin blocks, sectioned at 4 µm, and stained with haematoxylin and eosin 
(H&E). Pieces of tumours were snap frozen in liquid nitrogen for further 
protein, DNA and RNA analysis.  Additional cohorts of 8 six-week-old female 
mice were injected with 1×106 cells via the tail vein. 
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7. Results 
 
7.1 Results of the first study 
 
Polycomb targets are specifically silenced in FOLFIRI non-responders 
Through an analysis on Oncomine database, we found that PcG targets are 
silenced in FOLFIRI nonresponder, compared with FOLFIRI responder, mCRC 
patients (P < 0.01, odds 4.6). Thus, EZH2 seems to be more active in FOLFIRI-
resistant patients. For this reason, we selected mCRC patients treated with 
FOLFIRI in combination with bevacizumab. 
 
Patient characteristics and treatment outcome 
One hundred and ten patients treated with FOLFIRI plus bevacizumab were 
identified; patient characteristics are listed in Table 1.One hundred and six 
patients were assessable for response (4 patients were not assessable because 
they had no measurable disease, i.e. peritoneal carcinomatosis); complete 
response was reported in 13 patients (12%) and partial response in 55 (52%), 
thus resulting in overall RR of 64%. Twenty-nine (27%) subjects achieved 
disease stabilization as best response, while nine (8%) progressed during 
treatment. Eight (7%) patients underwent secondary radical (R0) surgical 
resection of metastases. At a median follow-up of 18.9 months, 72 patients 
experienced disease progression (patients not assessable for RR were included 
in the PFS analysis since they experienced unequivocal disease progression by 
the appearance of new lesions in different organs) and 40 patients have died; 
median PFS and OS were 9.9 and 23.3 months, respectively. 
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Table 1. Patients characteristics. ECOG Eastern Cooperative Oncology Group. 
a for three    patients, Kohne score was not assessable due to missing data. 
 
Genotype information 
Genotype frequencies found in our population are reported in Table 2. All 
polymorphisms follow Hardy–Weinberg equilibrium. SNP frequencies are 
comparable with those reported in a previous study on a Caucasian population 
[17].  
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Table 2. EZH2 polymorphisms: associations with RR, PFS and OS 
 
Correlation between EZH2 SNPs and outcome 
Correlations between EZH2 SNPs, RR and clinical outcome parameters are 
summarized in Table 2. No significant association was detected between 
genotypes and RR (P > 0.05 for all comparisons). Similarly, 553G>C, 
2110+6A>C and 9177211T>C variants did not show significant association 
with clinical outcome. Concerning 626-394C>T, median PFS of patients 
carrying the three variants (T/T, T/C and C/C) were 11.2, 10.1 and 8.7 months, 
respectively (P = 0.029). These three genotypes did not differ significantly in 
terms of median OS (18.3, 27.9 and 23.8 months, respectively; P = 0.148). We 
noticed a similar PFS between T/T and T/C patients [hazard ratio (HR) = 1.158, 
95% confidence interval (CI) 0.690–1.945; P = 0.578], while a statistically 
significant difference was reported comparing T/T or T/C with C/C patients 
(HR = 0.260, 95% CI 0.097–0.695; P = 0.007 and HR = 0.345, 95% CI 0.134–
0.890; P = 0.028, respectively). This observation prompted us to compare 
clinical outcome between C/C homozygotes and subjects carrying at least one T 
allele. When compared with patients with at least one T allele, C/C 
homozygotes showed significantly shorter median PFS (11.0 versus 8.7months; 
HR = 0.269, 95% CI 0.102–0.706; P = 0.008) (Figure 1A) and OS (23.8 versus 
18.3 months; HR = 0.329, 95% CI 0.109–0.997; P = 0.049) (Figure 1B). 
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Figure 1. (A) PFS according to 626-394C>T genotype. (B) OS according to 
626-394C>T genotype. PFS, progression-free survival; OS, overall survival. 
 
Cox model and interaction test 
To test the hypothesis that 626-394C>T SNP is an independent prognostic 
factor in our population, we carried out a Cox regression including all variables 
known to possibly affect PFS or OS in patients. At multivariate analysis, C/C 
genotype retained its significant association with worse PFS (HR = 2.211, 95% 
CI 1.057–4.624; P = 0.035) (Table 3). This difference reflected into a 
significantly shorter OS (HR = 2.851, 95% CI 1.024–7.938; P = 0.045) (Table 
3). Another factor found to be associated with worse PFS and OS in our series 
was mucinous histology. 
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Table 3. Multivariate Analysis 
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In silico and in vivo characterization of 626-394C>T polymorphism 
The 626-394C>T SNP was reported as an intronic polymorphism, located 
between exons 6 and 7 [17]. Due to the putative role of this variant in mCRC 
patients, we investigated if the T–C change at this residue may alter TF binding 
or splicing sites in exons 6 and 7. For this purpose, we used PROMO3.0 
software and NCBI Aceview databases. The latter tool revealed that 23 EZH2 
splice variants have been described. None of these includes the residue hosting 
the 626-394C>T variant (data not shown). To the contrary, the T allele may 
create a binding site for the XBP1 factor. To confirm our prediction, we 
measured EZH2 expression in peripheral lymphocytes from 50 CRC patients. 
We also analyzed 626-394C>T SNP in these patients. As shown in Figure 2, the 
C/C variant was associated with a significantly higher EZH2 expression, with 
respect to C/T and T/T genotypes (P < 0.05). Interestingly, EZH2 levels were 
not significantly different between C/T and T/T genotypes. 
 
 
 
Figure 2. EZH2 mRNA levels in 50 CRC patients. Gene expression in 
lymphocytes is relative to GAPDH levels. *P < 0.05 (ANOVA, Bonferroni 
post-test). mRNA, messenger RNA; CRC, colorectal cancer; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; ANOVA, analysis of variance. 
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7.2 Results of the second study 
 
7.2.1 EZH2 overexpression and modulation by DZNeP 
The mRNA expression of EZH2 was detectable in all PDAC cells, as well as in 
the originator tissues of the primary tumor cell cultures. This expression 
differed among cells, ranging from 0.100 a.u. in LPc006 cells to 0.644 a.u. in 
PL45 cells (Fig. 1A). The mean expression in the tumor cells (0.372±0.174 a.u.) 
was similar to the median (0.360 a.u.), and significantly higher (P<0.01) than 
the expression detected in hTERT-HPNE cells (0.037 a.u.), and in fibroblasts 
(0.027 a.u.). EZH2 gene expression in the 7 primary tumor cells and their 
originator tumors showed a similar pattern and were highly correlated with 
Spearman analysis (R2=0.89, P=0.01). PANC-1, MIA-PaCa-2 and LPc006 cells 
were selected for further studies, because of previous studies on expression of 
the CD133 CSC marker (24, 26), and their differential levels of EZH2. The 
expression of EZH2 was also studied at protein level, both in untreated cells 
and in cells treated with 5 µM DZNeP for 24 or 72 hours. As shown in Fig. 1B, 
DZNeP reduced the expression of EZH2, especially after 72 hours (e.g. 48%, 
32% and 36% reduction of EZH2 in PANC-1, MIA-PaCa-2 and LPc006 cells, 
respectively). In addition, we investigated the expression of the H3K27me3 
protein, which was also reduced after 72 hours exposure. Finally, since previous 
studies reported that DZNeP is a S-adenosylhomocysteine hydrolase inhibitor, 
we verified this inhibition and measured the intracellular concentration of its 
product adenosine in PANC-1 cells by a specific LC-MS/MS method (16). 
Adenosine was significantly reduced after 72-hour exposure to DZNeP (Fig. 
1C), indicating that S-adenosylhomocysteine hydrolase was significantly 
inhibited. 
63 
 
 
 
Figure 1. EZH2 expression and DZNeP activity in PDAC cells. (A) EZH2 mRNA 
expression in cell lines (grey-bars), primary tumor cultures (white-bars), and their 
originator tissues (blackbars); (B) Effect of 5 µM DZNeP on the expression of EZH2 and 
H3K27me3 after 72 hours; (C) Modulation of adenosine by 5 µM DZNeP after 72 hours, 
as detected by LC-MS/MS. Columns, mean values obtained from three independent 
experiments. 
 
Synergistic interaction of DZNeP with gemcitabine 
Treatment with DZNeP showed minimal growth inhibition in PANC-1 cells. 
More than 50% of these cells were still growing after exposure at the highest 
concentration (20 µM). MIA-PaCa-2 and LPc006 cells were much more 
sensitive, with IC50 values of 1.0±0.3 and 0.10±0.03 µM, respectively (Fig. 
2A-C). To the contrary, gemcitabine was highly cytotoxic, with IC50s of 
17.9±1.3 nM (PANC-1), 5.9±0.8 nM (MIA-PaCa-2), and 7.2±1.3 nM (LPc006). 
Based on these results, as well as the modulation of EZH2 protein by 5 µM 
DZNeP, combination studies were performed using a fixed concentration of 
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DZNeP at 5 µM. DZNeP enhanced the antiproliferative activity of gemcitabine, 
reducing the IC50s of gemcitabine to 5.02±1.31, 0.12±0.04 and 0.03±0.01 nM 
in PANC-1, MIA-PaCa-2, and LPc006. The mean CI showed slight-to-
moderate synergism in LPc006 cells, and strong synergism in the PANC-1 and 
MIAPaCa-2 cells (Fig. 2D). In order to evaluate the mechanisms underlying 
this synergistic interaction, several biochemical analyses were performed with 
the simultaneous combination, as detailed below. 
 
Figure 2. Inhibition of cell proliferation and pharmacological interaction of DZNeP 
and gemcitabine. Representative curves of growth inhibitory effects after 72 hours 
exposure to 5 µM DZNeP, gemcitabine at IC50 or their combination (drug concentrations 
on the X-axis are referred to gemcitabine) in PANC-1 (A), MIA-PaCa-2 (B) and LPc006 
(C); (D) Mean CI of the DZNeP/gemcitabine combination. CI values at FA of 0.5, 0.75 
and 0.9 were averaged for each experiment, and this value was used to calculate the mean 
between experiments, as described in the Materials and Methods section. Points and 
columns, mean values obtained from three independent experiments; bars, SEM. 
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DZNeP/gemcitabine combination enhanced apoptosis 
DZNeP, gemcitabine and their combination affected the cell cycle of PDAC 
cells (Table 1). In particular, DZNeP significantly reduced the percentage of 
PANC-1 cells in the G2/M phase from 27 to 19%, after 72 hours, while 
gemcitabine increased cells in G2/M phase to 36% (P<0.05). The drug 
combination significantly reduced the percentage of cells in the G2/M phase. 
Hence, DZNeP blocked PANC-1 cells in the G1-S boundary. Conversely 
gemcitabine reduced the cells in this phase and no modulation was detected 
after drug combination in the PANC-1 cells. 
Similar perturbations of the cell cycle were observed in MIA-PaCa-2 cells. 
However, in LPc006 the percentage of cells in the G2/M phase was 
significantly reduced both after DZNeP-alone and DZNeP/gemcitabine 
combination. Moreover, the DZNeP/gemcitabine combination significantly 
increased cells in the S-phase, while reducing cells in the G0/G1 phase. 
Analysis of the sub-G1 region demonstrated that drug treatments significantly 
enhanced cell death compared to control (Table 1). In particular, MIA-PaCa-2 
cells treated with the combination exhibited the largest sub-G1 signal (e.g., 
34%). Further analysis with fluorescence microscopy showed that cells exposed 
to DZNeP, gemcitabine and their combination presented a typical apoptotic 
morphology with cell shrinkage, nuclear condensation and fragmentation, and 
rupture of cells into debris, after 72-hour exposure. In all cell lines, 5-9% of 
apoptotic cells were observed after gemcitabine treatment, whereas DZNeP 
exposure was associated with a higher percentage (6-15%) of apoptotic cells; 
drug combination significantly increased the apoptotic index with respect to 
both control cells and gemcitabine-treated cells. 
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DZNeP/gemcitabine combination inhibited cell migration and up-regulated E-
cadherin 
To investigate the effects of DZNeP, gemcitabine and their combination on 
migratory behavior, a scratch assay was performed in PANC-1, MIA-PaCa-2 
and LPc006 cells. After exposure of PANC-1 cells to gemcitabine at IC50, 5 
µM of DZNeP and their combination, a significant reduction of migration was 
observed after 48 hours (Fig. 3A). In particular, the percentages of cellular 
migration in PANC-1 were approximately 70%, 60%, 53% and 38%, in 
untreated, gemcitabine, DZNeP and their combination treated cells, 
respectively. Inhibition of migration of MIA-PaCa-2 and LPc006 with DZNeP 
or DZNeP/gemcitabine combination was much more effective than in PANC-1 
cells (Fig. 3B-C). DZNeP significantly reduced cells migration with respect to 
controls, after 8 hours, with inhibition of about 20% in the reduction of scratch-
area in LPc006 cells. In addition, the combination was also significantly more 
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effective than DZNeP-alone after 48 hours in both MIA-PaCa-2 and LPc006 
cells. Since previous studies suggested that EZH2 repressed E-cadherin 
expression (27), we investigated whether DZNeP could affect the levels of this 
target at both mRNA and protein level. DZNeP and its combination with 
gemcitabine significantly enhanced E-cadherin mRNA expression (Fig. 3D). 
Similarly, immunocytochemistry analysis in LPc006 cells revealed a significant 
increase of E-cadherin protein staining after exposure to both DZNeP and 
DZNeP/gemcitabine combination (Fig. 3E). 
 
 
Figure 3. Effects of DZNeP, gemcitabine and their combination on PDAC cells 
migration. Results of wound-healing assay in PANC-1 (A), MIA-PaCa-2 (B) and LPc006 
(representative picture at 48 hours) (C) cells. Cells were exposed to 5 µM DZNeP, 
gemcitabine at IC50, and to their combination. Modulation of E-cadherin after 24 hours as 
determined by real-time RT-PCR (D) and immunocytochemistry (E) Columns, mean 
values obtained from three independent experiments; bars, SEM. *Significantly different 
from controls. 
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DZNeP/gemcitabine combination reduced PDAC spheroids and CD133+ cells 
Earlier studies illustrated that results of sensitivity to anticancer drugs, 
including gemcitabine, in two-dimensional monolayer cell culture models were 
different from three-dimensional (3-D) culture models (28). Moreover, the use 
of serum-free-cancer-stem cell medium should select a population harboring 
CSCs characteristics, which should be selectively targeted by inhibitors of 
DZNeP. Thus, in order to determine whether DZNeP would enhance the 
efficacy of gemcitabine in 3-D systems, we tested these drugs in spheroids of 
PANC-1, MIA-PaCa-2 and LPc006 cells. After 10 days of culture, we 
transferred in each well of 96-well plates about 10 spheroids that were 
approximately 500 µm in diameter (Fig. 4A-B). These growing spheroids were 
exposed to DZNeP, gemcitabine and their combination for 72 hours. The 
growth of these spheroids was only slightly inhibited by gemcitabine (Fig. 4C), 
while DZNeP significantly reduced their volume. However, the 
DZNeP/gemcitabine combination remarkably increased the disintegration of 
these spheroids, which were significantly reduced in size compared to the 
spheroids exposed to gemcitabine-alone in all our three PDAC models. 
Spheroids from each treatment group were collected and used for PCR 
evaluation of CD133, which was significantly higher than in adherent cells 
(data not shown). This CSC-marker was significantly increased after 
gemcitabine exposure, whereas DZNeP reduced its mRNA levels. Moreover the 
DZNeP/gemcitabine combination significantly reduced CD133 expression in 
both PANC-1 and LPc006 cells, as shown in Fig. 4D. 
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Figure 4. Effects of DZNeP, gemcitabine and their combinations on PDAC spheroids. 
Representative pictures of PANC-1 spheroids in a 96-well plate (A), and example (original 
magnification 40X) of the measurement of the diameters of one spheroid (B); Effect of 5 
µM DZNeP, gemcitabine at IC50 values, and their combination on the volumes of PDAC 
spheroids (C) and CD133 mRNA expression (D), after 72 hours exposure. Columns, mean 
values obtained from three independent experiments; bars, SEM. *Significantly different 
from controls. 
 
DZNeP and DZNeP/gemcitabine combination reduced deoxynucleotides and 
increased hENT1 and hCNT1 expression. 
Treatment of PANC-1 cells with gemcitabine, DZNeP and their combination 
decreased the cellular concentrations of all deoxynucleotides from -25% (dAΣP 
after DZNeP) to -65% (dAΣP after gemcitabine). Of note, the levels of dTΣP 
were depleted by all treatments to not detectable levels (Fig. 5A). These 
changes in the pools of deoxynucleotides were associated with a significant 
increase in the mRNA expression of hENT1, after exposure to DZNeP and its 
combination with gemcitabine (Fig. 5B). An increased expression of both 
hENT1 and hCNT1 transporters was also observed at the protein level (Fig. 
5C). 
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Figure 5. Effects of DZNeP, gemcitabine and their combination on phosphorylated 
deoxynucleosides and nucleoside transporters. (A) Modulation of the intracellular 
deoxynucleotides, dAΣP (dAMP, dADP and dATP), dCΣP (dCMP, dCDP and dCTP), 
dGΣP (dGMP, dGDP and dGTP) and dTΣP (dTMP, dTDP and dTTP), as detected by the 
LC-MS/MS. Modulation of hENT1 mRNA expression (B) and representative blot of the 
modulation of hENT1 and hCNT1 protein levels after 72 hours exposure to 5 µM DZNeP 
(C). Columns, mean values obtained from three independent experiments; bars, SEM. 
*Significantly different fromcontrols. 
 
 
7.2.2 CCA patient characteristics and responses. 
 Patient characteristics are summarized in TableI. The median ECOG 
performance status and median Ca19.9 level at diagnosis were 1 and 204IU/ml, 
respectively. Of the 74 evaluable patients, 3 complete responses (CR) were 
observed (4.1%), while a partial response (PR) was observed in 10 of 74 
evaluable patients (13.5%), stable disease (SD) in 34 patients (45.9%) and 
progressive disease (PD) in 27 patients (36.5%). A median follow-up of 
42.3months revealed that the median OS was 14.9months (8.2-21.6) and the 1-
year survival rate was 56%. 
71 
 
 
 
In silico characterization of g.148505302 C>T, g.148525904C>G, 
g.148519011C>T and g.148517456T>G.  
Among the 26 SNPs in the EZH2 locus described by Yoon etal (20), only 1 
SNP (g.148525904C>G) is located on an exon (exon 6) and is responsible for 
an amino acid change (histidine/aspartate). Conversely, 25 SNPs are located in 
EZH2 non-coding regions and they may affect EZH2 expression by affecting 
miRNA, transcription regulator binding or mRNA splicing. However, no SNPs 
affecting miRNA binding or splicing were identified, while the PROMO 3.0 
software detected noteworthy correlations between the allelic variants of 3 of 
these EZH2 SNPs and TFB sites (Fig. 1). In g.148505302 C>T, the T allele 
creates a binding site for the peroxisome proliferator-activated receptor 
(PPAR)-α/retinoid-X-receptor (RXR)-α . The C allele of g.148519011C>T 
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creates a binding site for E2F-1 and the G allele of g.148517456T>G creates a 
binding site for Pax-5 and p53. All these TFs are expressed in CCA cell 
lines(25-28).  
 
Figure 1. Identification of putative TFBS in DNA sequences. EZH2 SNPs may 
be responsible for differential TFB. (A) g.148519011 CC allows E2F-1 binding; 
(B) g.148517456 GG allows Pax-5 and tumor suppressor p53 binding; and (C) 
g.148505302 TT allows PPAR-α/RXR-α complex binding. TFBS, transcription 
factor binding sites; EZH2, Enhancer of zeste homolog 2; SNPs, single 
nucleotide polymorphisms; TFB, transcription factor binding. 
 
SNP genotyping. 
 The 4 SNPs selected (TableII) were successfully evaluated in all available 
DNA samples. The g.148505302 C>T, g.148519011C>T and g.148525904C>G 
SNPs were in Hardy-Weinberg equilibrium. Conversely, the g.148517456T>G 
SNP did not follow the Hardy-Weinberg equilibrium. However, all SNPs had 
frequencies comparable to those observed in Caucasian populations reported in 
Pubmed Reference-SNP (RefSNP).  
 
 
  Table II. Position and functional characteristics of the investigated SNPs. 
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EZH2 SNP correlation with clinical outcome.  
No significant correlations were identified between the g.148519011C>T, 
g.148525904C>G and g.148517456T>G SNPs and clinical outcome, while the 
g.148505302 C>T (rs887569) SNP had a significant association with OS. In 
particular, the patients harbouring the TT genotype had a significantly longer 
OS (TT vs. CT-CC, P=0.036; Fig. 2). Moreover, the TT genotype revealed a 
trend-like correlation with OS (P=0.075) in multivariate analysis. 
 
Figure 2. OS according to g.148505302 C>T genotype (rs887569). OS, overall 
survival.  
 
 
7.3 Results of the third study 
 
Oncomine Analysis 
Analysis of the Oncomine database revealed that low expression of Mel-18 is 
associated with a shorter time-to-tumor-recurrence after mastectomy in all BC sub-
types (p<0.001, fold-change: 2.043) (Figure 1A).  Mel-18 is selectively silenced in 
TNBC compared to other histologic subtypes (p=0.004, fold-change: 2.238) 
(Figure 1B).   
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Figure 1. A. Mel-18 expression in patients with no metastatic events, 5 years 
after mastectomy (46, left side) and patients with metastatic events at the same time 
(22, right side). B. Mel-18 expression in TNBCs (10, left side) and other BC sub-
types (130, right side).  
 
 
Polycomb group gene expression in different mammary cell lines 
We performed survival expression of EZH2, BMI-1 and Mel-18 in 16 cell lines (9 
triple negative tumor types, 1 Basal-like and 6 Luminal type). EZH2 is 
overexpressed in each BC cell lines, BMI-1 is overexpressed in several BC cell 
lines (MDA-MB-231, BT-549, SUM-159, BT-20, MDA-MB-453, SKBR3, MCF7, 
BT-474, T47D and ZR751); Mel-18 expression is high in Luminal Type BC cell 
lines (MDA-MB-453, MCF7 and BT474) and it is absent in TNBC cell lines. The 
Mel-18 expression is directly correlated with BMI-1 expression. In fact, when 
BMI-1 expression is high Mel-18 expression is high too, when BMI-1 expression is 
low, Mel-18 is low or not expressed (Figure 2). Mel-18 expression could play a key 
role in regulation of BMI-1.  
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Figure 2. Western Blot results of MCF10A derived cells and breast cancer cell 
lines of EZH2, Mel-18 and BMI-1 expression: HS578T-BT20: Triple Negative 
BC cell lines; MDAMB453-T47D: Luminal Type BC cell lines  
 
 
Mel18 suppress proliferation, migration and invasion of MCF10A, 
MCF10A+BMI1, MCF10A+H-RAS, MCF10A+BMI1+H-RAS  cells 
We previously demonstrated that overexpression of BMI1 or H-RAS alone and in 
combination markedly altered MCF10A morphology in 2D culture (ref). BMI1 and 
H-RAS cooperate to significantly increase cell proliferation, invasion, tumor 
formation and metastatic spreading in vivo. After the evaluation of Polycomb group 
gene expression in BC cell lines, we selected some cell lines showing high Mel-18 
expression in which we knocked-down Mel-18 using shRNA and some BC cell 
lines showing low Mel-18 expression in which we stably overexpressed Mel-18. 
Interestingly, BMI-1 expression increased in several BC cell lines following Mel-
18 overexpression. In particular, BMI-1 expression increased in MDA-MB-231 
cells that overexpress Mel-18. Rates of proliferation (Figure 3), migration  and 
invasion were increased in MCF7-sh-Mel18 cells and MCF10A-derived c-sh-
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          Figure 3. Proliferation Assay Graphs 
 
Apoptosis via activation of Caspase-3 and PARP in mammary cell line 
We investigated the levels of apoptosis in cells in response to etoposide using an 
antibody raised against the cleaved and active forms of Caspase-3 and PARP, a 
marker of cellular apoptosis. We detected no cleaved Caspase-3 and PARP positive 
cells in MCF10A and MCF7 cells. A low level of apoptosis was detected in 
mammary cell lines with overexpression of BMI1, H-RAS, BMI-1+H-RAS and 
Mel18 KD (MCF10A+BMI1shMel18, MCF10A+H-RASshMel18 and 
MCF10A+BMI1+H-RASshMel18), apoptosis increased in Mel-18 overexpressing 
MDAMB231 when compared to the basal cell line and control (cell line with empty 
vector). These results indicate that Mel18 knock down inhibits apoptosis, involving 
low cleavage of Caspase-3 and PARP (Figure 4). 
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    Figure 4. Western Blot of Caspase-3 and PARP 
 
             Mel-18 Knockdown induces EMT in MCF10A derived cells and breast Cancer 
             Cell lines 
When examining the morphology of MCF10A and Breast Cancer derived cells with 
Mel 18 knock-down we noticed that MCF10A+BMI shMel18acquired a spindle 
morphology. This modification could suggest an induction of an EMT phenotype in 
these cells (Figure 5). 
 
Figure 5. Morphology of MCF10A+BMI-1 control, ShMel18 X01 and ShMel18 
X04 
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 To confirm this, we performed western blot analysis of the cell lines for the 
expression of EMT markers. The results indicate that Vimentin increased in 
MCF10A derived cells and in MCF7 with where Mel18 was silenced, the same 
happened for CK14, Slug and Twist; Ck8 had a non consistent trend because its 
expression in MCF10A and MCF10A+H-Ras with Mel18 KD is decreased and 
increased in MCF10A+BMI-1 and MCF10A+BMI-1+H-RAS. Interestingly, we 
noticed loss of expression of E-cadherin in MCF10A derived cell and MCF7 with 
Mel18 KD . In MDAMB231+Mel18 we noticed a decrease of Vimentin, Slug and 
Twist expression and an increase of expression of CK8 and E-Cadherin. The 
increase of expression of Slug, Twist, Vimentin and CK14 together with the 
decrease of expression of E-cadherin  in MCF10A derived cells and MCF7 with 
Mel18 KD could explain   the increase in proliferation, migration and invasion 
shown above.  To evaluate whether reduced Mel18 expression could also alter 
expression of a metastasis associated gene, we evaluated LOXL2 expression in 
vitro. The majority of the cell lines with Mel18 KD showed an increase in LOXL2 
overexpression (Figure 6). Further in vivo experiments will confirm these results. 
 
     Figure 6. Western blot of EMT markers, LOXL2 and PcG genes (EZH2, BMI-1 
and Mel18) 
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Mel18 knockdown speeds tumour formation and progression in mammary fat pad 
xenografts and decrease the overall survival 
MCF10A+H-RAS+BMI1 cells expressing empty vector (control X06) or shRNA 
for Mel18 (ShMel18) were used for mammary fat pad and tail vein injection 
experiments.  Tumour volumes from MCF10A+H-RAS and MCF10A+BMI1 +H-
RAS fat pad xenografts with Mel18 KD were significantly bigger compared to cells 
with empty vector. Moreover MCF10A+H-RAS+BMI1 ShMel18 fat pad xenograft, 
the most aggressive cell line, showed an early tumor formation compared to 
MCF10A+H-RAS shMel18. All mice of the MCF10A+BMI-1+H-RAS ShMel18 
died in 20 days from the tumor formation, the Mice of MCF10A+H-RAS ShMel18 
lived longer but less of the MCF10A+BMI-1 ShMel18.  Taken together, these data 
demonstrate that decreasing the expression of Mel18 in these breast cancer cells 
leads to an increase in tumour progression and tumor aggressiveness (Figure 7A 
and 7B). Immunohistochemistry results will complete the in vivo studies and the 
metastasis spreading. 
 
 
Figure 7A. Tumor growth of mammary fat pad injection mice with MCF10A+Ras and     
MCF10A+BMI1+Ras  
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Figure 7B. Survival proportions of immunocompromised mice injected with 
MCF10A derived cells 
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8. Discussion  
 
In the first study, we showed that 626-394C/C EZH2 genotype is associated with 
shorter PFS and OS in mCRC patients treated with FOLFIRI plus bevacizumab 
regimen. EZH2 is emerging as a novel oncogene and putative therapy target in 
oncology [1]. Along with its role in CSC self-renewal [2], EZH2 is known to silence 
several tumor suppressor genes, including CDH1 (E-cadherin) and 
p16INK4A/p14ARF [3, 4]. The latter event leads to uncontrolled proliferation and 
resistance to chemotherapy [5]. E-cadherin regulates CRC cell adhesion, growth and 
invasion. CDH1 silencing is an early step of epithelial-to-mesenchymal transition [6] 
and contributes to Wnt pathway activation [7], which in turn triggers 5-FU and 
irinotecan resistance in CRC cells [8]. Wnt pathway activation is also essential for 
colorectal CSC proliferation [9]. Thus, EZH2 may contribute to CSC self-renewal and 
chemotherapy resistance. Keeping with this hypothesis, high EZH2 expression has 
been associated with shorter OS and higher stage in CRC patients [10, 11]. The 626-
394C>T SNP is an intronic polymorphism [12]. Intronic SNPs may affect gene 
expression through several mechanisms, including changes in TF binding sites [13], 
microRNA target sequences [14] and splicing variants [4]. This SNP is not located on 
the 3# untranslated region, thus it does not likely affect microRNA binding. In 
addition, it is not involved in alternative splicing. Our in silico analysis revealed that 
the T allele may create a binding site for the XBP1 factor. Patients carrying the C/C 
genotype have no binding sites for this factor. XBP1 is a basic leucine zipper (b-zip) 
TF [15,16], which is activated by cellular stress (i.e. hypoxia, DNA damage). XBP1 
dimerizes with other b-zip proteins, thereby binding specific DNA sequences. XBP1-
containing heterodimers may lead to modulation of different set of genes [17]. XBP1 is 
expressed by CRC cells, and its up-regulation leads to cell death [18]. Interestingly, 
DNA damage is known to trigger EZH2 down-regulation [19]. It is conceivable that, in 
response to cellular stress, XBP1 inhibits EZH2 expression in colorectal CSCs. In 
patients carrying at least one T allele, EZH2 expression may be inhibited by XBP1. In 
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C/C homozygotes, EZH2 expression could be deregulated, thereby producing more 
aggressive tumors. Keeping with this hypothesis, we found that EZH2 mRNA levels 
are higher in C/C patients, compared with other genotypes (Figure 2 of the first study). 
 The C/T and T/T genotypes did not show a significantly different EZH2 expression. 
Unfortunately, due to the lack of adequately processed samples for mRNA analysis in 
the mCRC patient cohort at the time the study was carried out, we decided to 
investigate EZH2 expression in a homogeneous series of radically resected CRC 
patients. Thus, our data suggest that C/C homozygous individuals show both poorer 
prognosis and higher EZH2 expression. Heterozygous genotype was not associated 
with intermediate EZH2 expression and prognosis. Several regulatory mechanisms may 
account for the same expression levels in C/T and T/T individuals. For example, XBP1 
up-regulation may reduce EZH2 expression in C/T but not in C/C patients (lacking 
XBP1 binding site). For other genetic variants, it has been reported that homozygous 
wildtype and heterozygous individuals show identical gene expression levels, while 
only homozygous mutant individuals demonstrate significantly different expression 
[20]. Other mechanisms may explain the prognostic role of the 626-394C>T variant in 
mCRC patients. For example, the 626-394C>T variant is in linkage disequilibrium with 
several other EZH2 polymorphisms [21], which may play a more determinant role. 
Thus, our in silico prediction needs to be mechanistically confirmed. Through their 
activity on Wnt pathway [17] and CSC selfrenewal [11], EZH2 variants likely affect 
CSC chemoresistance. As already mentioned, CSCs represent _3% of the total tumor 
mass [22], but they are responsible for tumor progression and treatment resistance [23]. 
Based on these assumptions, it was predicted that CSC-related gene variants mainly 
affect PFS and OS, without a measurable effect on RR as assessed by conventional 
radiological criteria [24]. Indeed, we found that 626-394C/C genotype predicted worse 
PFS and OS but not lower RR. The lack of correlation with treatment activity could be 
also explained by the high RR (64%) in our retrospective series. However, median PFS 
and OS times in our population are in line with those reported in randomized [25] and 
observational [25] trials with FOLFIRI plus bevacizumab, thus reducing the risks of 
major selection bias. More importantly, the C/C genotype emerged as an independent 
predictor of shorter PFS and OS at multivariate analyses. The C/C variant seemed to 
predict PFS with higher sensitivity than other prognostic variables. Mucinous histology 
was significantly associated with worse PFS and OS at multivariate analysis. These 
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results confirm previous reports suggesting the impact of mucinous histology on both 
benefit from treatment and OS in mCRC patients treated with first-line chemotherapy. 
To conclude, this is the first experience suggesting that an EZH2 polymorphism has 
significant impact on clinical outcome in oncology. Despite this, our investigation has 
some limitations that should be pointed out: it is a retrospective study, conducted on a 
small population and with a relatively short follow-up for OS (18.9 months). Thus, our 
exploratory data need to be confirmed by larger prospective independent series in order 
to overcome possible bias inherent to retrospective evaluations. In particular, to explore 
the predictive value of this SNP, an adequately powered prospective randomized trial 
should be carried out.  
 
The second study on PDAC demonstrates that the combination of the EZH2 inhibitor 
DZNeP, and the cytotoxic compound gemcitabine, was strongly synergistic in a panel 
of PDAC cells characterized by different molecular properties. The highly lethal nature 
of PDAC makes multiple areas of research a priority, including assessment of novel 
targets that might prevent or suppress the proliferative, invasive and chemoresistant 
behavior of PDAC cells. EZH2 has a master regulatory role in the fate of native 
embriogenic cells (26), as well as in cancer development via methylation-mediated 
repression of transcription of several genes (27, 28). Overexpression of EZH2 is a 
marker of advanced and metastatic disease in many solid tumors, including PDAC 
(29,30), and EZH2 nuclear accumulation is strongly associated with poor 
differentiation and prognosis of PDAC (31, 32). Previous studies on PANC-1 and 
SW1990 showed that suppression of EZH2 expression by RNA interference with 
Lentiviral-shEZH2 markedly inhibited cellular proliferation in vitro, and drastically 
diminished both tumorigenecity and liver metastasis in vivo (33). Furthermore, the 
transfection of shEZH2 construct cells sensitized MIA-PaCa-2 and Pac04.02 to 
doxorubicin and gemcitabine (32), suggesting that combination of EZH2 inhibitors 
with gemcitabine might overcome the intrinsic chemoresistance of PDAC. To our 
knowledge, this is the first study evaluating the pharmacological interaction of the 
small molecule EZH2 inhibitor DZNeP with gemcitabine in PDAC cells (Fig. 6).  
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Figure 6. Molecular mechanisms involved in the synergistic interaction of DZNeP 
with gemcitabine. (A) Structures of gemcitabine and (B) DZNeP (C); DZNeP enhanced 
the growth inhibitory effects of gemcitabine through its pronounced pro-apoptotic, anti-
invasive effects, as well as by inhibiting spheroids growth. Furthermore, modulation of 
phosphorylated deoxynuclosides and nucleoside transporters promotes gemcitabine uptake. 
 
The expression of EZH2 was detectable in all our PDAC cells, including 7 primary 
tumor cell cultures, in their first passages, where the levels of EZH2 mRNA were 
comparable to their originator tumors, suggesting that these cells represent optimal 
preclinical models for our pharmacological studies. Conversely, EZH2 levels were 
significantly lower in both fibroblasts and in the normal pancreatic ductal cells HPNE, 
in agreement with earlier data on normal pancreatic tissue and specimens from patients 
affected by pancreatitis (31). Since DZNeP inhibits S-adenosylhomocysteine 
hydrolase, a component of the methionine cycle, resulting in accumulation of the 
inhibitory S-adenosylhomocysteine, its effects on histone methylation is global rather 
than EZH2 specific (33, 34), and we evaluated both the modulation of H3K27me3 
expression and the perturbation of intracellular adenosine. In our PDAC cells, using 
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concentrations and exposure time (5 µM, 72 hours) similar to those used in other tumor 
cells (35), we observed a significant reduction of both EZH2 and H3-K27 expression, 
as well as a dramatic decrease of intracellular adenosine content. Although DZNeP 
alone did not significantly affect proliferation of PANC-1 and MIA-PaCa-2 cells, these 
data suggested that DZNeP effectively reached its targets. A recent phase-III trial 
showed that the oxaliplatin/irinotecan/fluorouracil/leucovorin (FOLFIRINOX) regimen 
is an option for the treatment of metastatic patients with good performance status, but 
was associated with increased toxicity (36). Thus, gemcitabine is still the standard first-
line agent (37), and several studies are evaluating novel strategies to improve its 
activity against PDAC. In the present study we demonstrated that DZNeP/gemcitabine 
combination was synergistic in two representative PDAC cell lines, PANC-1 and MIA-
PaCa-2, and in the primary cell culture LPc006. This synergistic interaction against cell 
proliferation was associated with a significant increase in apoptosis induction. This 
effect may be related to cell cycle modulation, which was also important for the 
efficacy of the combination of the histone-deacetylase inhibitor trichostatin-A with 
gemcitabine (38). Cellular damage induced by chemotherapeutic drugs such as 
gemcitabine can convert some targets of EZH2 into critical survival factors. In this 
context, the blockade of EZH2 after the exposure to cytotoxic drugs could prevent cell-
damage repair, leading to apoptosis. In particular, previous studies in breast cancer 
cells resistant or sensitive to DZNeP led to the identification of a set of PRC2 target 
genes including TGFBI, IGFBP3, and PPPIR15A, which are involved in apoptosis, 
while TGFB signaling pathway is frequently deregulated in PDAC (39). However, our 
findings show that the synergistic interaction of DZNeP with gemcitabine is also 
mediated by other mechanisms, which reduced PDAC aggressiveness and enhanced 
sensitivity to gemcitabine. Since one of the major hallmarks and problems in the 
therapy of PDAC is its early local and systemic dissemination, we evaluated whether 
DZNeP might affect cell migration. In agreement with previous studies, showing that 
inhibition of EZH2 by DZNeP, attenuated glioblastoma and mesothelioma cell 
migration/invasion (40), we observed that inhibition of EZH2 by DZNeP and its 
combination with gemcitabine significantly reduced cell migration, as detected with 
wound-healing assay. Several classes of proteins are participating to invasive PDAC 
phenotype, including cell-cell adhesion molecules like members of immunoglobulin 
and calcium-dependent cadherin families and integrins. One widely observed alteration 
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in cell-to-environment interaction in PDAC involves E-cadherin, which couples 
adjacent cells by E-cadherin bridges, and a recent study showed that recruitment of 
histone deacetylases HDAC1/HDAC2 by the transcriptional repressor ZEB1 
downregulates E-cadherin expression in PDAC (41). Keeping with previous evidence 
on inverse relationship between EZH2 and E-cadherin expression (31), also our data 
show that DZNeP-induced EZH2 inhibition resulted in an increase in both mRNA and 
protein expression of E-cadherin. Recently PDAC also emerged as a CSC-driven 
disease (42). This might at least partially explain its chemoresistant nature, and 
compounds targeting critical developmental genes keeping self-renewal in CSCs, 
including Sonic hedgehog, BMI-1 and EZH2, seem promising anticancer agents. For 
example the Curcumin-analog CDF inhibited formation of pancreatospheres as well as 
PDAC growth by switching on several suppressor microRNAs and attenuating EZH2 
expression (43). DZNeP significantly reduced the volume of PDAC spheroids growing 
in serum-free-stem-cell medium. Gemcitabine only slightly reduced the volume of 
these spheroids, possibly by affecting some remaining bulk tumor cells, but it increased 
the expression of the CSC-marker CD133, as observed previously (44), suggesting that 
exposure to gemcitabine might select a population of more aggressive cells. 
Conversely, DZNeP was able to effectively deplete the most aggressive subpopulation 
of PDAC cells, as suggested by the significant reduction of both spheroids and CD133 
expression. In addition to the effects of DZNeP on migration and spheroids, the present 
study also showed that it interfered with pivotal determinants for the activity of 
gemcitabine. In particular, different thymidylate synthase inhibitors upregulated 
hENT1 and increased gemcitabine sensitivity by depleting intracellular nucleotide 
pools (45-46). Therefore, we analyzed the cellular deoxynucleotides pools and 
modulation of the expression of key nucleoside transporters (47). Gemcitabine, DZNeP 
and their combination significantly depleted all the endogenous deoxynucleotides. The 
results achieved after exposure to gemcitabine might be explained by gemcitabine-
induced inhibition of ribonucleotide reductase, as reported previously (48). DZNeP is 
not phosphorylated and does not get incorporated into DNA (49), but it markedly 
reduced endogenous deoxynucleotides. This might at least in part explain the 
significant up-regulation of both hENT1 and hCNT1, potentially facilitating 
gemcitabine cytotoxicity. In conclusion, inhibitors of EZH2, such as DZNeP, seem 
very promising anticancer agents, by attacking key mechanisms involved in the 
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proliferation, cell cycle control, apoptosis and of migration properties of PDAC cells. 
Moreover, the favorable modulation of hENT1/hCNT1 transporter makes DZNeP an 
optimal candidate for combination with gemcitabine. The synergistic results observed 
in the present study may have critical implications for the rational development of 
innovative regimes including DZNeP and gemcitabine to improve the efficiency of the 
actual treatment of PDAC.  
 
The second study on CCA revealed that the g.148505302 T allele is associated with a 
longer OS in CCA patients. The g.148505302 C>T SNP is located in intron 19 of the 
EZH2 gene (50). Through in silico analysis it was revealed that the T allele creates a 
binding site for the PPAR-α/RXR-α heterodimer. The PPARs were identified in 1990 
by Issemann and Green(51). PPARs are ligand-activated transcription factors that 
directly influence the transcription of target genes(52). Three related PPAR isotypes 
have been identified (PPAR-α, -β/δ and -γ) (53). PPAR-α binds to DNA as a 
heterodimeric complex with RXR-α (54). This complex binds to a specific sequence in 
regulatory regions of target genes, known as peroxisome proliferator response element 
(PPRE), with two copies of a hexameric nucleotide sequence, TGACCT-like (54). 
Several studies have suggested differential mechanism underlying the role of PPAR-α 
in cancer, including key roles in modulation of cell-cycle genes, cell proliferation and 
cellular apoptosis (55). In accordance with these hypotheses, the g.148505302 T allele, 
which binds the PPAR-α/RXR-α complex, may trigger mechanisms involved in 
apoptosis and cell proliferation inhibition by downregulation of the EZH2 oncogene. 
EZH2 is a transcriptional repressor involved in cell proliferation (56). Overexpression 
of EZH2 is associated with aggressive and metastatic disease in various types of 
cancer(57), including CCA. In particular, EZH2 is not expressed in the cholangiocytes 
or hepatocytes of livers without tumors, but is overexpressed in poorly differentiated 
carcinoma(58). Therefore, EZH2 expression may be a predictor of the biological 
aggressiveness and poor prognosis in CCA (59). Cell culture studies have confirmed 
the expression of EZH2 mRNA in CCA cells, but not in normal cells (58). These 
studies have also demonstrated that when EZH2 is decreased by suberoylanilide 
hydroxamic acid (SAHA; a histone deacetylase inhibitor) treatment, the tumor 
suppressors p16, E-cadherin and p21 are activated (58). Previous studies have shown 
that EZH2 expression had a stepwise increase in aggressive and invasive CCA (59, 60). 
88 
 
Since EZH2 drives CSC self-renewal and is associated with poor prognosis in most 
malignancies, it is conceivable that these cells contribute to the maintenance of the 
tumoral mass and are implicated in CCA chemoresistance.  
EZH2 expression and activity may be affected by functional polymorphisms. SNP 
genotyping is particularly attractive for tumors detected in the advanced stages, 
including CCA, since it is an easy-to-perform analysis. This analysis may be performed 
with a small volume of biological fluids (e.g. 200µl of blood specimens) in less than 
24h.  
The current study demonstrates how a candidate EZH2 SNP may be a novel biomarker 
correlated with clinical outcome in CCA patients. Due to the relatively small sample 
size and retrospective design, further studies are required in order to validate the 
prognostic role of this SNP in CCA. Our in silico prediction should also be extended by 
appropriate molecular analyses, which go beyond the scope of the present analysis. In 
addition, the possibility that the g.148505302 C>T SNP is in linkage disequilibrium 
with other polymorphic variants, which may be responsible for the prognostic 
significance of this marker, cannot be ruled out.  
In conclusion, to the best of our knowledge, this is the first study to show an EZH2 
SNP having a significant impact on CCA outcome, possibly through its role in the 
PPAR-α/RXR-α complex interaction with EZH2. If these results are confirmed by 
larger prospective studies, this EZH2 polymorphism may be useful for predicting the 
clinical outcome in CCA patients. 
 
In the third study, based on recent publications that linked Mel-18 expression to a 
better prognosis in breast cancer, we investigated the potential prognostic role of Mel-
18 in BC molecular sub-types and in relation to the PcG complex 1 competitor BMI-1.  
At first, we conducted a gene expression analysis through Oncomine database 
(oncomine.com) that showed Mel-18 down-regulation associated with a shorter time-to 
tumor- recurrence after mastectomy in all BC sub-types, and a silencing in TNBC, 
compared to other histologies.  
Interestingly, a recent publication showed that oncogenic PcG members, like BMI-
1 are selectively up-regulated in TNBC, thus this particular BC sub-type may be 
characterized by over-expression of oncogenic PcGs like BMI-1 and EZH2  and 
silencing of tumor-suppressive PcGs like Mel-18. Our previous  in vitro and in vivo 
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studies demonstrate that the overexpression of BMI1 alone does increase rates of 
proliferation and invasion and inhibits the apoptotic response to DNA damage.  
Moreover ,we showed that these effects were significantly augmented in the context of 
H-RAS, which is overexpressed in up to 20-30% of human breast cancers (61).  
Additionally, the overexpression of BMI1 in MCF10A cells overexpressing H-Ras 
resulted in a marked spindle-like change in cell morphology, increased proliferation, 
increased invasive properties and resistance to apoptosis in vitro. We further 
demonstrated that BMI1 collaborates with H-Ras to greatly enhance metastatic 
propensity to the lung  and unusual dissemination of metastases to the brain using a tail 
vein model in mice (62).  Although the structures of BMI-1 and Mel-18 appear very 
similar, it is not known whether Bmi-1 and Mel-18 contribute to cancer cell growth and 
survival in similar ways. To understand the functional molecular basis of this 
relationship, we evaluated the expression of these genes in several BC cell lines.  We 
demonstrated that Mel-18 expression is generally high in luminal type BC cells and is 
low or absent in TNBC type cells.  On the basis of gene expression analysis, we 
performed KD or overexpression of Mel-18 in BC cell lines and in BMI-1, H-Ras and 
BMI-1+H-Ras overexpressing MCF10A. The Mel-18 overexpression in TNBC cell 
line MDAMB231 decreases the migration and invasion of the cells when compared to 
the control (empty vector) and the basal cell line. Consistent with these findings, BC 
cell lines and MCF10A derived cells with the KD of Mel18 showed a significant 
increase in proliferation, migration and invasion and a decrease in the cleavage of 
apoptosis markers PARP and Caspase-3 in vitro.  Moreover, preliminary in vivo results 
conducted on immunocompromised SCID mice with Mel-18 KD derived cells showed 
an early tumor formation and a shorter overall survival when injected in the mammary 
fat pad (Figure 7A, 7B). 
 These results give a notable contribution to the understanding of Mel-18 function 
related to BMI-1 expression. To investigate more in deep this role we analyzed several 
EMT markers expression, confirming our discoveries for several of the BC and 
MCF10A derived cell lines studied. 
During this study we tried to further understand the relationship between BMI-1 
and Mel18 and tumor biology. Surprisingly, we noticed that in BMI-1 and H-Ras 
overexpressing MCF10A cells, after the Mel-18 KD there was a decrease of BMI-1 
expression instead of an overexpression as expected. Based on this result we believe 
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that the association between BMI-1 and Mel-18 expression to the biological functional 
may be cell context dependent, although it is thought that they can act competitively.  
In conclusion we have shown that Mel18 has a pivotal role for tumor suppression, 
resulting in less aggressive cancer cell behavior. Moreover,depending on the cellular 
context, Mel-18 can alter proliferative and invasive properties and lead to the up or 
down- regulation of BMI-1, suggesting that a breast cancer tumor with low Mel-18 
expression may trigger some mechanisms to alter  BMI-1 expression and its 
availability, leading to a more aggressive tumor related to a poor prognosis. These 
findings allow us to understand more the whole mechanism of interaction between 
Mel-18 and BMI-1 in BC in general, and particularly in TNBC. Further in vivo results 
will complete our study. 
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